<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81177</article-id><article-id pub-id-type="doi">10.7554/eLife.81177</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Cyclic AMP is a critical mediator of intrinsic drug resistance and fatty acid metabolism in <italic>M. tuberculosis</italic></article-title></title-group><contrib-group><contrib contrib-type="author" id="author-285197"><name><surname>Wong</surname><given-names>Andrew I</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285198"><name><surname>Beites</surname><given-names>Tiago</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-285199"><name><surname>Planck</surname><given-names>Kyle A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208780"><name><surname>Fieweger</surname><given-names>Rachael A</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-306024"><name><surname>Eckartt</surname><given-names>Kathryn A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285200"><name><surname>Li</surname><given-names>Shuqi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8133-6838</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-285201"><name><surname>Poulton</surname><given-names>Nicholas C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83973"><name><surname>VanderVen</surname><given-names>Brian C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3655-4390</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-104497"><name><surname>Rhee</surname><given-names>Kyu Y</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-107751"><name><surname>Schnappinger</surname><given-names>Dirk</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-103150"><name><surname>Ehrt</surname><given-names>Sabine</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7951-2310</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-283541"><name><surname>Rock</surname><given-names>Jeremy</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9310-951X</contrib-id><email>rock@rockefeller.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0420db125</institution-id><institution>Laboratory of Host-Pathogen Biology, The Rockefeller University</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02r109517</institution-id><institution>Department of Microbiology and Immunology, Weill Cornell Medicine</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02r109517</institution-id><institution>Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05bnh6r87</institution-id><institution>Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University</institution></institution-wrap><addr-line><named-content content-type="city">Ithaca</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rp50x72</institution-id><institution>University of the Witwatersrand</institution></institution-wrap><country>South Africa</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rp50x72</institution-id><institution>University of the Witwatersrand</institution></institution-wrap><country>South Africa</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>22</day><month>02</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e81177</elocation-id><history><date date-type="received" iso-8601-date="2022-06-17"><day>17</day><month>06</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-02-22"><day>22</day><month>02</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-07-07"><day>07</day><month>07</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.07.07.499113"/></event></pub-history><permissions><copyright-statement>© 2023, Wong et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Wong et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81177-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-81177-figures-v2.pdf"/><abstract><p>Cyclic AMP (cAMP) is a ubiquitous second messenger that transduces signals from cellular receptors to downstream effectors. <italic>Mycobacterium tuberculosis</italic> (Mtb), the etiological agent of tuberculosis, devotes a considerable amount of coding capacity to produce, sense, and degrade cAMP. Despite this fact, our understanding of how cAMP regulates Mtb physiology remains limited. Here, we took a genetic approach to investigate the function of the sole essential adenylate cyclase in Mtb H37Rv, Rv3645. We found that a lack of <italic>rv3645</italic> resulted in increased sensitivity to numerous antibiotics by a mechanism independent of substantial increases in envelope permeability. We made the unexpected observation that <italic>rv3645</italic> is conditionally essential for Mtb growth only in the presence of long-chain fatty acids, a host-relevant carbon source. A suppressor screen further identified mutations in the atypical cAMP phosphodiesterase <italic>rv1339</italic> that suppress both fatty acid and drug sensitivity phenotypes in strains lacking <italic>rv3645</italic>. Using mass spectrometry, we found that Rv3645 is the dominant source of cAMP under standard laboratory growth conditions, that cAMP production is the essential function of Rv3645 in the presence of long-chain fatty acids, and that reduced cAMP levels result in increased long-chain fatty acid uptake and metabolism and increased antibiotic susceptibility. Our work defines <italic>rv3645</italic> and cAMP as central mediators of intrinsic multidrug resistance and fatty acid metabolism in Mtb and highlights the potential utility of small molecule modulators of cAMP signaling.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd><italic>M. tuberculosis</italic></kwd><kwd>cAMP</kwd><kwd>antibiotic resistance</kwd><kwd>metabolism</kwd><kwd>fatty acids</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source><award-id>INV-004709</award-id><principal-award-recipient><name><surname>Rhee</surname><given-names>Kyu Y</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P01AI143575</award-id><principal-award-recipient><name><surname>Schnappinger</surname><given-names>Dirk</given-names></name><name><surname>Ehrt</surname><given-names>Sabine</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01130018</award-id><principal-award-recipient><name><surname>VanderVen</surname><given-names>Brian C</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>NIH Tuberculosis Research Units Network</institution></institution-wrap></funding-source><award-id>U19AI162584</award-id><principal-award-recipient><name><surname>Rhee</surname><given-names>Kyu Y</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Department of Defense</institution></institution-wrap></funding-source><award-id>PR192421</award-id><principal-award-recipient><name><surname>Rock</surname><given-names>Jeremy</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Robertson Therapeutic Development Fund</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rock</surname><given-names>Jeremy</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>NIH/NIAID New Innovator Award</institution></institution-wrap></funding-source><award-id>1DP2AI144850-01</award-id><principal-award-recipient><name><surname>Rock</surname><given-names>Jeremy</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The ubiquitous second messenger cyclic AMP, produced by Rv3645/MacE, controls long-chain fatty acid metabolism and intrinsic multidrug resistance in <italic>M. tuberculosis</italic>.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p><italic>Mycobacterium tuberculosis</italic> (Mtb) has evolved complex signaling and regulatory networks to sense and adapt to the diverse niches through which it transits during infection (<xref ref-type="bibr" rid="bib22">Johnson and McDonough, 2018</xref>; <xref ref-type="bibr" rid="bib44">Parish, 2014</xref>; <xref ref-type="bibr" rid="bib47">Richard-Greenblatt and Av-Gay, 2017</xref>). The physiology that enables Mtb to adapt to and persist in the host can also decrease the effectiveness of antibiotics (<xref ref-type="bibr" rid="bib7">Bellerose et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">Larrouy-Maumus et al., 2016</xref>). For example, hypoxia reduces Mtb respiratory capacity and activates the DosRST two-component system (<xref ref-type="bibr" rid="bib45">Park et al., 2003</xref>). DosR induces a 48 gene regulon which ultimately slows growth, promoting survival under hypoxic conditions and tolerance to antibiotics that are more active against rapidly replicating bacteria (<xref ref-type="bibr" rid="bib19">Galagan et al., 2013</xref>). In a second example, nutrient starvation results in the dephosphorylation of CwlM, a substrate of the eukaryotic-like protein serine/threonine kinase PknB (<xref ref-type="bibr" rid="bib9">Boutte et al., 2016</xref>). Dephosphorylation reduces CwlM interaction with and activation of the peptidoglycan biosynthetic enzyme MurA, thereby reducing cell wall metabolism and promoting tolerance to starvation and antibiotics. Thus, the signaling and regulatory networks that facilitate Mtb survival under diverse physiologic conditions can also secondarily reduce the effectiveness of antibiotics. While several examples have been described, it is clear that numerous poorly understood signaling mechanisms exist that promote Mtb survival while reducing the effectiveness of antibiotic therapy (<xref ref-type="bibr" rid="bib7">Bellerose et al., 2020</xref>).</p><p>In addition to two-component systems and serine/threonine kinases, one of the most ubiquitous signal transduction modalities in Mtb is the adenylate cyclases. Adenylate cyclases sense extracellular or intracellular signals, either directly or indirectly, and transduce this signal into a cellular response by converting ATP into the small molecule second messenger 3’,5’-cyclic-AMP (cAMP) and pyrophosphate (<xref ref-type="bibr" rid="bib22">Johnson and McDonough, 2018</xref>). cAMP then binds to and alters the function of effector proteins like the transcription factor CRP (<xref ref-type="bibr" rid="bib55">Stapleton et al., 2010</xref>), the protein lysine acetyltransferase Mt-Pat (<xref ref-type="bibr" rid="bib38">Nambi et al., 2013</xref>), and numerous other potential cAMP-binding proteins (<xref ref-type="bibr" rid="bib22">Johnson and McDonough, 2018</xref>) to modify Mtb gene expression or gene product activity. Whereas the model bacteria <italic>E. coli</italic> encodes only one adenylate cyclase, the adenylate cyclase gene family has undergone a remarkable expansion in mycobacteria. <italic>M. avium</italic>, <italic>M. marinum</italic>, and Mtb encode 12, 31, and at least 15 predicted adenylate cyclases (<xref ref-type="bibr" rid="bib52">Shenoy and Visweswariah, 2006</xref>), respectively. The existence of so many adenylate cyclases in the Mtb genome presumably allows Mtb to integrate diverse signals with downstream cellular responses by using cAMP as a second messenger. Mtb adenylate cyclases can be activated by a variety of stimuli, including pH (<xref ref-type="bibr" rid="bib56">Tews et al., 2005</xref>), bicarbonate (<xref ref-type="bibr" rid="bib10">Cann et al., 2003</xref>), and fatty acids (<xref ref-type="bibr" rid="bib1">Abdel Motaal et al., 2006</xref>), with the resulting increase in cAMP levels modulating both bacterial and host physiology (<xref ref-type="bibr" rid="bib2">Agarwal et al., 2009</xref>). This expansion of the adenylate cyclase gene family is mirrored by an expansion of predicted cAMP phosphodiesterases, effectors, and binding proteins (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>) – nearly 1% of the Mtb genome is predicted to produce, degrade, or interact with cAMP. However, despite the clear importance of cAMP signaling in mycobacteria, our knowledge of how adenylate cyclases and cAMP regulate Mtb physiology remains largely undefined.</p><p>To address this gap, we undertook a genetic study of the sole in vitro essential adenylate cyclase in Mtb H37Rv, <italic>rv3645</italic>. We found that a lack of <italic>rv3645</italic> resulted in increased sensitivity to numerous antibiotics by a mechanism independent of substantial increases in envelope permeability. We further found that <italic>rv3645</italic> was conditionally essential for Mtb growth in the presence of long-chain fatty acids, a host-relevant carbon source, and identified mutations in the atypical cAMP phosphodiesterase <italic>rv1339</italic> that suppress this fatty-acid-dependent essentiality. Quantifying cAMP levels revealed that Rv3645 is the dominant source of cAMP under standard laboratory growth conditions. Bacterial cAMP levels were not altered by the presence of long-chain fatty acids nor the presence of some antibiotics to which <italic>rv3645</italic> mutants were more sensitive, suggesting that Rv3645 does not sense the presence of long-chain fatty acids or antibiotics. Rather, cAMP produced by Rv3645, presumably in response to an alternative signal, puts the bacilli in a physiologic state capable of surviving the stresses of long-chain fatty acids and antibiotics. Together, our work defines Rv3645 and the ubiquitous second messenger cAMP as central mediators of intrinsic multidrug resistance and fatty acid metabolism in Mtb.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>The essential adenylate cyclase Rv3645 contributes to intrinsic drug resistance in Mtb H37Rv</title><p>To identify genes and pathways that influence drug efficacy in Mtb, we previously screened a genome-wide CRISPRi library in Mtb strain H37Rv against a panel of diverse antibiotics (<xref ref-type="bibr" rid="bib32">Li et al., 2022</xref>). This approach identified hundreds of Mtb genes whose inhibition altered bacterial fitness in the presence of partially inhibitory drug concentrations, including genes encoding the direct drug target and non-target hit genes. Amongst the non-target hit genes, we found that depletion of the predicted essential adenylate cyclase, <italic>rv3645</italic> (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), sensitized Mtb to numerous antibiotics with unrelated mechanisms of action (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Mtb H37Rv encodes 15 putative adenylate cyclases that are expressed at various levels in standard laboratory culture conditions (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A,B</xref>). Interestingly, <italic>rv3645</italic> was the only adenylate cyclase whose knockdown resulted in increased drug sensitivity (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), demonstrating a lack of substantial functional redundancy for adenylate cyclases under these culture conditions. Given the predicted essentiality of <italic>rv3645</italic> and the magnitude by which silencing of this gene sensitized Mtb to various antibiotics, we next sought to better characterize the role of this gene in Mtb physiology.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The adenylate cyclase <italic>rv3645</italic> is critical for intrinsic multidrug resistance in <italic>Mycobacterium tuberculosis (Mtb)</italic>.</title><p>(<bold>A</bold>) Predicted domain organization of Rv3645. N-terminal transmembrane helices, HAMP domain, and C-terminal cytosolic adenylate cyclase domain (CHD) are shown. HAMP = Histidine kinases, Adenylate cyclases, Methyl-accepting proteins, and Phosphatases; CHD = Cyclase Homology Domain. (<bold>B</bold>) Feature-expression heatmap of <italic>rv3645</italic> from a 5 day CRISPRi library pre-depletion screen. The color of each circle represents the gene-level log2 fold change (L2FC); a white dot represents a false discovery rate (FDR) &lt;0.01 and a |L2FC|&gt;1. VAN = vancomycin; CLR = clarithromycin; RIF = rifampicin; BDQ = bedaquiline; EMB = ethambutol; LVX = levofloxacin; STR = streptomycin; INH = isoniazid; LZD = linezolid. Each antibiotic was tested in triplicate at three sub-minimum inhibitory concentrations (sub-MIC90) listed in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>. (<bold>C</bold>) Growth of <italic>rv3645</italic> CRISPRi strains on 7H10-OADC agar. Columns represent 10-fold serial dilutions in cell number. NT = non-targeting sgRNA; KD = knockdown; CS = CRISPRi-sensitive; CR = CRISPRi-resistant. (<bold>D–G</bold>) Dose-response curves for (<bold>D</bold>) vancomycin, (<bold>E</bold>) rifampicin, (<bold>F</bold>) clarithromycin, and (<bold>G</bold>) linezolid were measured against <italic>rv3645</italic> CRISPRi strains. Data represent mean ± SEM for technical triplicates and are representative of at least two independent experiments.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Antibiotic concentrations (nanomolar) used for CRISPRi chemical-genetic interaction screens.</title><p>Each antibiotic was tested at three sub-MIC90 concentrations in biological triplicate (<xref ref-type="bibr" rid="bib32">Li et al., 2022</xref>).</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81177-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title><italic>rv3645</italic> contributes to multidrug intrinsic resistance in H37Rv Mycobacterium tuberculosis (Mtb).</title><p>(<bold>A</bold>) Feature-expression heatmap of annotated adenylate cyclase, cAMP phosphodiesterase, putative cNMP binding protein, cAMP storage, and cAMP effector genes from a 5 day CRISPRi library pre-depletion screen (<xref ref-type="bibr" rid="bib32">Li et al., 2022</xref>). The color of each circle represents the gene-level L2FC; a white dot represents a false discovery rate (FDR) &lt;0.01 and a |L2FC|&gt;1. VAN = vancomycin; CLR = clarithromycin; RIF = rifampicin; BDQ = bedaquiline; EMB = ethambutol; LVX = levofloxacin; STR = streptomycin; INH = isoniazid; LZD = linezolid. (<bold>B</bold>) Expression of 15 adenylate cyclase genes in Mtb H37Rv. Transcript abundance for each gene in WT Mtb H37Rv, plotted as RPKM generated by RNA-seq transcriptional profiling. RPKM = reads per kilobase of transcript, per million reads mapped. Data represent mean ± SEM for biological triplicates. (<bold>C–H</bold>) Dose-response curves for meropenem (<bold>C</bold>), bedaquiline (<bold>D</bold>), isoniazid (<bold>E</bold>), clofazimine (<bold>F</bold>), ethambutol (<bold>G</bold>), and levofloxacin (<bold>H</bold>). NT = non-targeting; KD = knockdown; CS = CRISPRi-sensitive; CR = CRISPRi-resistant. Data represent mean ± SEM for technical triplicates and are representative of three independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-fig1-figsupp1-v2.tif"/></fig></fig-group><p>We first sought to validate the screen results. To do this, we cloned a single-guide RNA (sgRNA) targeting <italic>rv3645</italic> into an inducible CRISPRi plasmid that allows for targeted <italic>rv3645</italic> knockdown in the presence of anhydrotetracycline (ATc) (<xref ref-type="bibr" rid="bib50">Rock et al., 2017</xref>). We also cloned complementation constructs expressing CRISPRi-sensitive or CRISPRi-resistant <italic>rv3645</italic> alleles (<xref ref-type="bibr" rid="bib61">Wong and Rock, 2021</xref>). These <italic>rv3645</italic> complementation alleles differ only by silent mutations within the <italic>rv3645</italic> ORF that abrogate CRISPRi targeting in the resistant allele but do not affect the wild-type protein sequence. Consistent with prior screens (<xref ref-type="bibr" rid="bib8">Bosch et al., 2021</xref>; <xref ref-type="bibr" rid="bib13">DeJesus et al., 2017</xref>), knockdown of <italic>rv3645</italic> prevented growth on 7H10-OADC agar plates (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). This growth defect was complemented by expressing a CRISPRi-resistant but not a CRISPRi-sensitive <italic>rv3645</italic> allele, demonstrating that growth inhibition was indeed a result of silencing <italic>rv3645</italic>. To validate the results of the CRISPRi chemical-genetic screen, we measured the minimum inhibitory concentrations (MICs) of a panel of antibiotics against the <italic>rv3645</italic> CRISPRi strains. Consistent with the CRISPRi screening results, <italic>rv3645</italic> knockdown sensitized Mtb to vancomycin, rifampicin, clarithromycin, bedaquiline, and meropenem but not other drugs (<xref ref-type="fig" rid="fig1">Figure 1D–G</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C–H</xref>). These results validate that the sole essential adenylate cyclase Rv3645 contributes to the intrinsic resistance of Mtb H37Rv to various antibiotics.</p></sec><sec id="s2-2"><title>Increased drug sensitivity in <italic>rv3645</italic> knockdown strains is not due to large increases in envelope permeability</title><p>The mycobacterial cell envelope serves as a permeability barrier that restricts access to antibiotics to their intracellular or periplasmic targets (<xref ref-type="bibr" rid="bib5">Batt et al., 2020</xref>). The similarities between the chemical-genetic signatures of <italic>rv3645</italic> and envelope biosynthetic genes (<xref ref-type="fig" rid="fig2">Figure 2A</xref>; <xref ref-type="bibr" rid="bib32">Li et al., 2022</xref>) suggested that <italic>rv3645</italic> may contribute to intrinsic drug resistance by promoting envelope integrity in Mtb. To test this hypothesis, we used a fluorescent, BODIPY-conjugated analog of vancomycin (BODIPY-VAN) to monitor drug uptake. Vancomycin is a large, polar antibiotic for which disruption of the Mtb envelope is known to increase drug uptake and increase drug sensitivity (<xref ref-type="bibr" rid="bib32">Li et al., 2022</xref>). Surprisingly, despite the dramatic sensitization of <italic>rv3645</italic> knockdown strains to vancomycin (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), <italic>rv3645</italic> knockdown strains showed only a modest increase in BODIPY-VAN uptake (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) as compared to the positive control gene <italic>mtrA</italic>, encoding a two-component response regulator important for proper envelope biogenesis (<xref ref-type="bibr" rid="bib32">Li et al., 2022</xref>). To ensure the discrepancy between <italic>rv3645</italic> MIC assays and drug uptake measurements was not due to the presence of the BODIPY conjugate (~274 Daltons), we first confirmed that BODIPY-VAN retained similar antimicrobial activity to vancomycin (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). To ensure that the BODIPY-VAN uptake assay was not confounded by differential cell death and lysis (cells which presumably would not stain with BODIPY-VAN), we confirmed that no loss in colony forming units (CFU) occurred when treating this panel of Mtb strains with vancomycin for the same time scale as the uptake assay (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). To further test the uptake hypothesis, we next monitored drug uptake directly by mass spectrometry. Consistent with the BODIPY-VAN results, <italic>rv3645</italic> knockdown strains did not show elevated levels of vancomycin uptake (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Finally, we monitored envelope permeability with the reporter dyes ethidium bromide, calcein-AM, and BCECF-AM. As with the vancomycin uptake assays, <italic>rv3645</italic> knockdown strains were not hyperpermeable to these dyes, as compared to the positive control genes involved in envelope biosynthesis and integrity (<xref ref-type="fig" rid="fig2">Figure 2D–F</xref>). Taken together, these results demonstrate that depletion of <italic>rv3645</italic> does not result in large increases in Mtb envelope permeability. Thus, Rv3645-mediated intrinsic drug resistance must occur primarily by some other mechanism.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Increased drug sensitivity in <italic>rv3645</italic> knockdown strains is not due to large increases in envelope permeability.</title><p>(<bold>A</bold>) Feature-expression heatmap of genes important for Mycobacterium tuberculosis (Mtb) cell envelope biosynthesis from the 5 day CRISPRi library pre-depletion screen for select drugs. <italic>ccdA</italic> is an in vitro essential non-hit control gene unrelated to envelope biosynthesis. The color of each circle represents the gene-level L2FC; a white dot represents a false discovery rate (FDR) of &lt;0.01 and a |L2FC|&gt;1. VAN = vancomycin; CLR = clarithromycin; RIF = rifampicin; BDQ = bedaquiline; LZD = linezolid. (<bold>B</bold>) BODIPY-Vancomycin uptake of the indicated strains. Data represent mean ± SEM for three replicates and are representative of two independent experiments. ***, p&lt;0.001; ****, p&lt;0.0001. Statistical significance was assessed by one-way ANOVA. (<bold>C</bold>) Quantification of vancomycin and linezolid uptake by mass spectrometry for the indicated strains. Data represent mean ± SEM for technical triplicates. ns = not significant. Statistical significance was assessed by two-way ANOVA (GraphPad Prism). Percent Uptake values are listed in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>. (<bold>D–F</bold>) Ethidium bromide (<bold>D</bold>), Calcein-AM (<bold>E</bold>), and BCECF-AM (<bold>F</bold>) uptake of the indicated strains. NT = non-targeting sgRNA; KD = knockdown; CS = CRISPRi-sensitive; CR = CRISPRi-resistant. Data represent mean ± SEM for three technical replicates and are representative of at least two independent experiments. ****, p&lt;0.0001. Statistical significance was assessed by one-way ANOVA.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Antibiotic uptake in <italic>rv3645</italic> CRISPRi strains.</title><p>Percent uptake values of antibiotics quantified by mass spectrometry in <xref ref-type="fig" rid="fig2">Figure 2C</xref> for the indicated strains. Each condition was tested in technical triplicate. NT = non-targeting sgRNA; KD = knockdown; CS = CRISPRi-sensitive; CR = CRISPRi-resistant.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81177-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Validation of the BODIPY-conjugated vancomycin uptake assay.</title><p>(<bold>A</bold>) Dose-response curves for vancomycin and BODIPY-vancomycin were measured for the indicated <italic>Mycobacterium tuberculosis</italic> (Mtb) strains. NT = non-targeting sgRNA; KD = knockdown; CS = CRISPRi-sensitive; CR = CRISPRi-resistant. Data represent mean ± SEM for technical triplicates. (<bold>B</bold>) Time-kill curves for the indicated Mtb strains grown in 1.16 µM vancomycin, equivalent to the concentration of BODIPY-vancomycin used in the uptake assay in <xref ref-type="fig" rid="fig2">Figure 2B</xref>. Gray shading highlights 30 min of vancomycin exposure, corresponding to the time scale of the BODIPY-vancomycin uptake assay. Vancomycin was added at 0 hr and monitored for 96 hr. The limit of detection in this assay was 100 CFU/mL. CFU = colony forming units.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-fig2-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title><italic>rv3645</italic> essentiality and contribution to intrinsic drug resistance is conditional on the presence of long-chain fatty acids</title><p><italic>rv3645</italic> is essential for Mtb H37Rv growth in standard laboratory media (7H10+OADC supplement: oleic acid, albumin, dextrose, and catalase; <xref ref-type="fig" rid="fig1">Figure 1C</xref>). Curiously, when the same growth medium was instead supplemented without fatty acid (ADC), <italic>rv3645</italic> knockdown no longer inhibited growth (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), suggesting that <italic>rv3645</italic> is conditionally essential in the presence of oleic acid. Using fatty acid-free growth conditions, we were able to generate an <italic>rv3645</italic> deletion strain (Δ<italic>rv3645</italic>). Genetic identity was confirmed through whole genome sequencing. Plating of Δ<italic>rv3645</italic> in the presence or absence of oleic acid confirmed that <italic>rv3645</italic> is conditionally essential in the presence of this fatty acid (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). To determine which other fatty acids may render <italic>rv3645</italic> essential, we measured MICs of fatty acids of increasing carbon chain lengths. Δ<italic>rv3645</italic> was uniquely sensitive to long-chain fatty acids palmitic acid (C16:0), oleic acid (C18:1), and arachidonic acid (C20:4); but not too short or medium-chain fatty acids or cholesterol (<xref ref-type="fig" rid="fig3">Figure 3B–D</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B–G</xref>). Notably, sensitivity was not observed towards the odd chain fatty acids propionic acid and valeric acid nor to cholesterol, ruling out propionate-derived toxicity as the source of the fatty acid-sensitive growth phenotype (<xref ref-type="bibr" rid="bib16">Eoh and Rhee, 2014</xref>). The fact that the growth of Δ<italic>rv3645</italic> in the presence of long-chain fatty acids was not rescued by alternative carbon sources in the medium (glycerol and glucose) suggests that long-chain fatty acids are toxic to Δ<italic>rv3645</italic>, rather than Δ<italic>rv3645</italic> being unable to consume them. Consistent with this interpretation, Δ<italic>rv3645</italic> showed elevated uptake and metabolism of [1-<sup>14</sup>C]-oleic acid (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>rv3645</italic> essentiality and contribution to intrinsic drug resistance is conditional on the presence of long-chain fatty acids.</title><p>(<bold>A</bold>) Growth of Δ<italic>rv3645</italic> deletion strains on 7H10-ADC agar in the presence or absence of oleic acid. EV = empty vector. (<bold>B–D</bold>) Dose-response curves for fatty acids palmitic acid (<bold>B</bold>), oleic acid (<bold>C</bold>), and arachidonic acid (<bold>D</bold>). Data represent mean ± SEM for technical triplicates and are representative of at least three independent experiments. (<bold>E</bold>) Uptake of [1-<sup>14</sup>C]-oleic acid in indicated strains. Uptake rates were calculated from the incorporated radioactive counts (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Statistical significance was determined by one-way ANOVA. Data are representative of two experiments. (<bold>F</bold>) Catabolic release of <sup>14</sup>CO<sub>2</sub> from [1-<sup>14</sup>C]-oleic acid in the indicated strains. Data are normalized to cell number as estimated by OD<sub>600</sub>, quantified relative to wild-type (WT), and represent means +/- SEM from technical triplicates, and are representative of two experiments. OE = over-expression, ns = not significant; ****, p&lt;0.0001. Statistical significance was determined by one-way ANOVA. (<bold>G–I</bold>) Dose-response curves for vancomycin (<bold>G</bold>), rifampicin (<bold>H</bold>), and clarithromycin (<bold>I</bold>) of the indicated strains grown in 7H9 with (OADC) or without (ADC) oleic acid. Data represent mean ± SEM for technical triplicates and are representative of at least two independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Δ<italic>rv3645</italic> does not sensitize <italic>Mycobacterium tuberculosis</italic> (Mtb) to short- or medium-chain fatty acids or cholesterol.</title><p>(<bold>A</bold>) Growth of <italic>rv3645</italic> CRISPRi strains on fatty acid-free 7H10-ADC agar. NT = non-targeting sgRNA; KD = knockdown; CS = CRISPRi-sensitive; CR = CRISPRi-resistant. (<bold>B–G</bold>) Dose-response curves for short-chain fatty acids acetic acid (<bold>B</bold>), propionic acid (<bold>C</bold>), butyric acid (<bold>D</bold>), and valeric acid (<bold>E</bold>); medium-chain fatty acid octanoic acid (<bold>F</bold>), and cholesterol (<bold>G</bold>). Data represent mean ± SEM for technical triplicates and are representative of three independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>[1–<sup>14</sup> C]-oleic acid uptake kinetic data.</title><p>Representative [1-<sup>14</sup>C]-oleic acid uptake data used to calculate oleic acid uptake rates for <xref ref-type="fig" rid="fig3">Figure 3E</xref> and <xref ref-type="fig" rid="fig5">Figure 5G</xref>. EV = empty vector; OE = over-expression.</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Spreadsheet of [1-<sup>14</sup>C]-oleic acid uptake rates in indicated strains.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81177-fig3-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-fig3-figsupp2-v2.tif"/></fig></fig-group><p>We next sought to determine if the contribution of <italic>rv3645</italic> to intrinsic drug resistance is also dependent on the presence of long-chain fatty acids. As with the growth defect, drug sensitivity associated with Δ<italic>rv3645</italic> was also dependent on the presence of long-chain fatty acids in the growth media (<xref ref-type="fig" rid="fig3">Figure 3G–I</xref>). These results demonstrate that <italic>rv3645</italic> essentiality and contribution to intrinsic drug resistance are both conditional on the presence of long-chain fatty acids.</p></sec><sec id="s2-4"><title>Loss-of-function of the atypical cAMP phosphodiesterase <italic>rv1339</italic> rescues fatty acid and drug sensitivity phenotypes of the Δ<italic>rv3645</italic> strain</title><p>Thus far, our results suggest that Rv3645 plays an important role in long-chain fatty acid metabolism in Mtb. To begin to interrogate how Rv3645 may contribute to lipid metabolism, we conducted a CRISPRi screen to identify suppressors of the fatty acid-dependent growth defect of Δ<italic>rv3645</italic>. An ATc-inducible CRISPRi library consisting of 96,700 sgRNAs targeting 4,054/4,125 of all Mtb genes was transformed into Δ<italic>rv3645</italic> (<xref ref-type="fig" rid="fig4">Figure 4A</xref>; <xref ref-type="bibr" rid="bib8">Bosch et al., 2021</xref>). The resulting Δ<italic>rv3645</italic> CRISPRi library was then cultured on 7H10 agar in the presence of ATc and in the presence or absence of a toxic concentration of palmitic acid. As expected, growth was markedly reduced in the presence of palmitic acid. Colonies that grew in the presence of palmitic acid were expected to harbor sgRNAs that silence genes that contribute to fatty acid toxicity in Δ<italic>rv3645</italic>. Colonies were harvested from both culture conditions and their sgRNAs were PCR amplified, deep sequenced, and counted to compare sgRNA representation +/– palmitic acid. Hit genes were identified by MAGeCK (<xref ref-type="bibr" rid="bib31">Li et al., 2014</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Loss-of-function of the atypical cAMP phosphodiesterase Rv1339 rescues fatty acid and drug sensitivity phenotypes of Δ<italic>rv3645</italic> strains.</title><p>(<bold>A</bold>) Schematic of the Δ<italic>rv3645</italic> CRISPRi suppressor screen. First, an inducible genome-wide CRISPRi library was cloned into Δ<italic>rv3645</italic> Mtb. The CRISPRi library was then expanded before plating on 7H10-ADC agar supplemented with anhydrotetracycline (ATc) in the presence or absence of an inhibitory concentration of palmitic acid (200 μM). Genomic DNA from surviving bacteria was prepared for sgRNA deep sequencing to identify genes whose inhibition permitted the growth of an Δ<italic>rv3645</italic> strain in the presence of palmitic acid. (<bold>B</bold>) List of all enriched hit genes (log2 fold change (L2FC)&gt;2 and false discovery rate (FDR)&lt;0.01) from the suppressor screen described in panel (<bold>A</bold>). (<bold>C</bold>) Spontaneous suppressors of Δ<italic>rv3645</italic> oleic acid sensitivity were isolated and genomes were sequenced. Identified mutations in <italic>rv1339</italic> are shown. (<bold>D</bold>) Growth of Δ<italic>rv3645</italic> CRISPRi suppressor strains. EV = empty vector; NT = non-targeting sgRNA; KD = knockdown. (<bold>E</bold>) Vancomycin dose-response curves of the indicated Δ<italic>rv3645</italic> strains. Data represent mean ± SEM for technical triplicates and are representative of at least two independent experiments.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>MAGeCK screen hits and results.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81177-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-fig4-v2.tif"/></fig><p>The suppressor screen identified nine enriched genes, eight of which encode structural or catalytic subunits of the Mce1 transporter (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>). Mce1 has recently been shown to be an importer of fatty acids, including palmitic acid, in Mtb (<xref ref-type="bibr" rid="bib39">Nazarova et al., 2017</xref>). Thus, Δ<italic>rv3645</italic> Mce1 knockdown strains likely fail to import palmitic acid, thereby allowing growth in the presence of this fatty acid. The fact that knockdown of the Mce1 transporter allows Δ<italic>rv3645</italic> to grow in the presence of palmitic acid suggests that the fatty acid toxicity phenotype of Δ<italic>rv3645</italic> is dependent on palmitic acid uptake and metabolism, consistent with recent results (<xref ref-type="bibr" rid="bib18">Fieweger et al., 2023</xref>), rather than an uptake-independent toxicity mechanism such as fatty acid-dependent disruption of the Mtb envelope (<xref ref-type="bibr" rid="bib23">Kengmo Tchoupa et al., 2022</xref>).</p><p>The top hit in the CRISPRi suppressor screen was the non-essential gene <italic>rv1339</italic> (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Consistent with the loss of Rv1339 activity suppressing the fatty acid sensitive phenotype of an Δ<italic>rv3645</italic> strain, isolation of spontaneous suppressors of Δ<italic>rv3645</italic> grown in the presence of oleic acid identified five unique mutations in <italic>rv1339</italic>, including one frameshift mutation (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). We confirmed that CRISPRi knockdown of <italic>rv1339</italic> rescued Δ<italic>rv3645</italic> fatty acid sensitivity with individual strains (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). To test whether loss of Rv1339 also suppresses the fatty acid-dependent drug sensitivity phenotype, we performed MIC assays in an Δ<italic>rv3645 rv1339</italic> knockdown strain. <italic>rv1339</italic> knockdown rescued the vancomycin sensitivity phenotype of the Δ<italic>rv3645</italic> strain (<xref ref-type="fig" rid="fig4">Figure 4E</xref>).</p><p>Intriguingly, Rv1339 was recently reported to be an atypical cAMP phosphodiesterase (<xref ref-type="bibr" rid="bib57">Thomson et al., 2022</xref>). While Rv3645 is the sole essential adenylate cyclase in H37Rv, it is possible that one or more of the other 14 additional adenylate cyclase homologs encoded in the genome (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A, B</xref>) could also be synthesizing cAMP under these growth conditions. In this case, the knockdown of the cAMP-degrading enzyme Rv1339 could restore cAMP levels in an Δ<italic>rv3645</italic> strain. These results strongly implicate cAMP levels in coordinately regulating fatty acid metabolism and intrinsic drug resistance in Mtb.</p></sec><sec id="s2-5"><title>The second messenger cAMP is a critical mediator of fatty acid metabolism and multidrug intrinsic resistance in Mtb</title><p>To test the hypothesis that cAMP regulates fatty acid metabolism and intrinsic drug resistance in Mtb, we first sought to test whether <italic>rv3645</italic> mutants incapable of synthesizing cAMP could complement these phenotypes. We cloned an <italic>rv3645</italic> allele with a point mutation in a metal-coordinating residue known to be essential for adenylate cyclase catalytic activity (<xref ref-type="bibr" rid="bib34">Linder et al., 2002</xref>). The Rv3645 adenylate cyclase catalytic mutant was unable to complement oleic acid and vancomycin sensitivity phenotypes (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). We confirmed by western blot that the catalytic mutant expressed at wild-type levels, and thus we attribute the lack of complementation specifically to the loss of cAMP synthesis (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>The second messenger cyclic AMP (cAMP) is a critical mediator of fatty acid metabolism and multidrug intrinsic resistance in <italic>Mycobacterium tuberculosis</italic> (Mtb).</title><p>(<bold>A</bold>) Growth on 7H10-ADC +/- oleic acid of indicated Δ<italic>rv3645</italic> strains expressing an <italic>rv3645</italic> adenylate cyclase catalytic mutant (D411A). (<bold>B</bold>) Vancomycin dose-response curves of indicated CRISPRi strains with adenylate cyclase <italic>rv3645</italic>(<italic>D411A</italic>) catalytic mutant defective in cAMP production. EV = empty vector. Data represent mean ± SEM for technical triplicates. (<bold>C–E</bold>) cAMP measurement of the indicated strains. D180A is a catalytically dead <italic>rv1339</italic> allele. NT = non-targeting sgRNA; KD = knockdown; OE = over-expressed. Data represent mean ± SEM for technical triplicates. ns = not significant; *, p&lt;0.05; ****, p&lt;0.0001. Statistical significance was assessed by one-way ANOVA (GraphPad Prism). (<bold>F</bold>) Uptake of [1-<sup>14</sup>C]-oleic acid in indicated strains. Uptake rates were calculated from the incorporated radioactive counts (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Statistical significance was determined by one-way ANOVA. (<bold>G</bold>) Catabolic release of <sup>14</sup>CO<sub>2</sub> from [1-<sup>14</sup>C]-oleic acid in the indicated strains. Data are normalized to cell number as estimated by OD<sub>600</sub>, quantified relative to WT, represent means ± SEM from technical triplicates, and are representative of two independent experiments. OE = over-expression, ns = not significant; ***, p&lt;0.001; ****, p&lt;0.0001. Statistical significance was determined by one-way ANOVA. (<bold>H</bold>) Vancomycin dose-response curves of <italic>rv3645</italic> deletion mutants overexpressing <italic>rv1339</italic>. (<bold>I</bold>) Vancomycin dose-response curves of the indicated Δ<italic>rv3645</italic> strains grown in the presence (dotted lines) or absence (solid lines) of the adenylate cyclase Rv1625c agonist V-59. Data represent mean ± SEM for technical triplicates and are representative of at least two independent experiments. (<bold>J</bold>) Model for the involvement of cAMP in lipid metabolism and intrinsic drug resistance in Mtb. Under standard lab culture conditions (7H9/7H10 media), Rv3645/MacE is the dominant source of cAMP. cAMP regulates physiological processes through binding to transcription factors, post-translational modification enzymes, and other poorly understood effector proteins. Regulation through likely multiple of these effector proteins reduces long-chain fatty acid uptake and catabolism and promotes intrinsic multidrug resistance.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title><italic>rv3645</italic> catalytic mutant is expressed similar to the wild-type allele.</title><p>Western blot for C-terminally 6His-tagged <italic>rv3645</italic> alleles expressed in <italic>M. smegmatis</italic>. Western blot for RpoB as a loading control. Note the double band present in the anti-His blot may reflect the processing of the predicted N-terminal signal peptide of Rv3645.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Original Western blot image of <italic>rv3645</italic> catalytic mutant.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81177-fig5-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>ATP and pyrophosphate levels does not change in Δ<italic>rv3645</italic> or <italic>rv1339</italic> overexpression strains.</title><p>ATP (<bold>A</bold>) and pyrophosphate (<bold>B</bold>) levels were measured by mass spectrometry in the indicated strains. Ion counts were normalized to protein concentrations in each sample. PPi = pyrophosphate; EV = empty vector; KD = knockdown; OE = over-expression. Data represent mean +/- SEM for technical triplicates. ns = not significant. Statistical significance was assessed by one-way ANOVA (GraphPad Prism).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Expression of Mce1 complex proteins does not change in Δ<italic>rv3645</italic> or <italic>rv1339</italic> overexpression strains.</title><p>Whole-cell lysates of indicated strains were probed by western blotting using antibodies specific for the indicated Mce1 proteins and GroEL. Inset values indicate protein levels quantified by densitometry, expressed as a ratio relative to the corresponding protein, normalized to the GroEL levels in the same strain. GroEL quantification expressed relative to wild-type (WT). EV = empty vector, OE = over-expression.</p><p><supplementary-material id="fig5s3sdata1"><label>Figure 5—figure supplement 3—source data 1.</label><caption><title>Original Western blot images of Mce1 complex proteins and GroEL.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81177-fig5-figsupp3-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-fig5-figsupp3-v2.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 4.</label><caption><title>V-59 induces cyclic AMP (cAMP) production in Δ<italic>rv3645</italic>.</title><p>cAMP was measured by ELISA for the indicated strains after 24 hr of treatment with DMSO (<bold>A</bold>) or 10 µM V-59 (<bold>B</bold>). Data represent mean +/- SEM for technical duplicates. ****, p&lt;0.0001. Statistical significance was assessed by one-way ANOVA. We note that the magnitude of cAMP detected by ELISA is lower than quantified by mass spectrometry, likely reflecting differences in culture conditions and lysate preparation, but the relative changes in cAMP levels measured between strains remain similar across experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-fig5-figsupp4-v2.tif"/></fig><fig id="fig5s5" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 5.</label><caption><title>An inducible cyclic AMP (cAMP) response is not critical to modulate oleic acid sensitivity nor intrinsic drug resistance.</title><p>cAMP was measured by ELISA for the indicated strains after 24 hr of growth in 7H9 with (OADC) or without (ADC) oleic acid (<bold>A</bold>), or 24 hr of treatment with DMSO, vancomycin (VAN), rifampicin (RIF), or linezolid (LZD). All drugs were tested at 10 µM, above their MIC90. KD = knockdown; EV = empty vector; OE = over-expression. Data represent mean ± SEM for technical duplicates and are representative of four independent experiments. ns = not significant; *, p&lt;0.05; **, p&lt;0.01; ***, p&lt;0.001; ****, p&lt;0.0001. Statistical significance was assessed by one-way ANOVA. We note that the magnitude of cAMP detected by ELISA is lower than that quantified by mass spectrometry, likely reflecting differences in culture conditions and lysate preparation, but the relative changes in cAMP levels measured between strains remain similar across experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-fig5-figsupp5-v2.tif"/></fig><fig id="fig5s6" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 6.</label><caption><title>Depletion of cyclic AMP (cAMP) sensitizes Mtb HN878 to vancomycin and palmitic acid.</title><p>(<bold>A–B</bold>) Dose-response curves for <italic>rv3645</italic> CRISPRi (<bold>A</bold>) and <italic>rv1339</italic> over-expression (<bold>B</bold>) strains of lineage 2 Mtb HN878. NT = non-targeting sgRNA, KD = knockdown; EV = empty vector; OE = over-expression. Data represent mean ± SEM for technical triplicates and are representative of two independent experiments. (<bold>C</bold>) Growth on 7H10-ADC +/- palmitic acid of indicated strains.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-fig5-figsupp6-v2.tif"/></fig><fig id="fig5s7" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 7.</label><caption><title>Δ<italic>macE</italic> is hypersensitive to the cytochrome <italic>bc<sub>1</sub></italic> complex inhibitor Q203.</title><p>Dose-response curves for the indicated strains. EV = empty vector. Data represent mean ± SEM for technical triplicates for two independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-fig5-figsupp7-v2.tif"/></fig></fig-group><p>To validate that loss of Rv3645 reduces intracellular cAMP levels in Mtb grown in 7H9-OADC, we quantified cAMP levels by mass spectrometry. A 31-fold reduction in cAMP was observed in the <italic>rv3645</italic> deletion strain (<xref ref-type="fig" rid="fig5">Figure 5C</xref>) that could be rescued by the knockdown of <italic>rv1339</italic> (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Conversely, overexpression of <italic>rv1339</italic> in an otherwise wild-type background led to an 11-fold reduction in cAMP levels (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Overexpression of a catalytically dead <italic>rv1339</italic> allele did not reduce cAMP levels (<xref ref-type="fig" rid="fig5">Figure 5E</xref>; <xref ref-type="bibr" rid="bib57">Thomson et al., 2022</xref>). Reduction in cAMP levels in Δ<italic>rv3645</italic> and <italic>rv1339</italic> overexpressing strains did not alter levels of ATP nor pyrophosphate, involved in cAMP biosynthesis, indicating that the observed phenotypes are not caused by alterations in these metabolites (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>).</p><p>Consistent with the role of cAMP in regulating long-chain fatty acid metabolism and drug sensitivity, overexpression of <italic>rv1339</italic> resulted in elevated oleic acid uptake and metabolism and increased vancomycin sensitivity (<xref ref-type="fig" rid="fig5">Figure 5F–H</xref>). Elevated oleic acid uptake and metabolism were not mediated by changes in Mce1 protein expression levels (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>). To conclusively demonstrate that modulating cAMP levels is sufficient to regulate Mtb H37Rv antibiotic sensitivity, we treated Δ<italic>rv3645</italic> strains with V-59, a small molecule agonist of the adenylate cyclase Rv1625c that results in constitutive cAMP production (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4</xref>; <xref ref-type="bibr" rid="bib60">Wilburn et al., 2022</xref>). Addition of V-59 rescued the vancomycin sensitivity of Δ<italic>rv3645</italic> (<xref ref-type="fig" rid="fig5">Figure 5I</xref>). These results demonstrate the crucial role of cAMP in regulating long-chain fatty acid metabolism and multidrug intrinsic resistance in Mtb.</p><p>Rv3645 is the dominant source of cAMP under standard laboratory growth conditions (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). To test whether Rv3645 is necessary to elevate cAMP levels in response to long-chain fatty acids or antibiotics, we quantified cAMP levels in Δ<italic>rv3645</italic> and <italic>rv1339</italic> overexpressing strains exposed to long-chain fatty acids and/or antibiotics. The addition of oleic acid did not alter cAMP levels as compared to fatty-acid-free media (<xref ref-type="fig" rid="fig5s5">Figure 5—figure supplement 5A</xref>). While the presence of antibiotics variably increased cAMP levels (<xref ref-type="fig" rid="fig5s5">Figure 5—figure supplement 5B</xref>), there was no correlation between the drugs that result in elevated cAMP levels and those drugs that <italic>rv3645</italic>-KD is sensitized to (<xref ref-type="fig" rid="fig1">Figure 1B–D</xref>). Taken together, these results suggest that Rv3645 is not a detector of long-chain fatty acids or antibiotics, but rather that cAMP produced by Rv3645 puts the bacilli in a physiologic state capable of surviving these stresses.</p><p>Lastly, to determine whether Rv3645 plays a similar role in regulating fatty acid metabolism and multidrug intrinsic resistance beyond the reference Mtb strain H37Rv, we investigated <italic>rv3645</italic> in the lineage 2 strain HN878. Unlike H37Rv, <italic>rv3645</italic> was not essential for in vitro growth in standard lab culture conditions, consistent with prior screening results (<xref ref-type="bibr" rid="bib8">Bosch et al., 2021</xref>; <xref ref-type="bibr" rid="bib11">Carey et al., 2018</xref>). Despite this difference in essentiality, the reduction of cAMP levels sensitized HN878 to both vancomycin and palmitic acid (<xref ref-type="fig" rid="fig5s6">Figure 5—figure supplement 6</xref>). Taken together, these data are consistent with a critical role for cAMP in regulating fatty acid metabolism and intrinsic drug resistance in Mtb.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Our work defines <italic>rv3645</italic> and cAMP as central mediators of intrinsic multidrug resistance and fatty acid metabolism in Mtb H37Rv. <italic>rv3645</italic> knockdown resulted in increased sensitivity to antibiotics with diverse targets by a mechanism largely independent of increases in cell envelope permeability. Surprisingly, we found that <italic>rv3645</italic> was only essential in H37Rv in the presence of long-chain fatty acids. Suppression of long-chain fatty acid sensitivity was conferred by loss of the Mce1 transporter, presumably reflecting reduced fatty acid uptake, or inactivation of the atypical cAMP phosphodiesterase Rv1339. Consistent with these genetic results, using mass spectrometry we found that Rv3645 is the dominant source of cAMP under standard laboratory conditions in H37Rv, despite this strain encoding 14 additional adenylate cyclases in its genome. We propose naming Rv3645 “MacE” for the <underline>m</underline>ajor <underline>a</underline>denylate <underline>c</underline>yclase <underline>e</underline>nzyme. Using gain- and loss-of-function alleles and small molecule-regulated cAMP production, we show that reduced cAMP levels are associated with elevated oleic acid uptake and metabolism, long-chain fatty acid toxicity, and increased drug sensitivity.</p><p>MacE is predicted to be composed of six transmembrane helices and cytosolic HAMP and cyclase homology domains. The presence of a HAMP domain, which typically transmits conformational changes from a periplasmic or transmembrane ligand binding domain to a cytoplasmic signaling domain (<xref ref-type="bibr" rid="bib21">Hulko et al., 2006</xref>), suggests that MacE senses a ligand and transduces this signal into cytoplasmic cAMP production. The nature of this signal remains to be determined, but it is unlikely to be long-chain fatty acids or antibiotics. Rather, our data suggest that MacE is active in the presence or absence of long-chain fatty acids and antibiotics, and that cAMP produced by MacE puts the bacilli in a physiologic state capable of surviving these stresses.</p><p>Why does a lack of <italic>macE</italic> and lowered cAMP levels make Mtb more sensitive to long-chain fatty acids and drugs? Prior work established a link between cAMP and fatty acid catabolism through the cAMP-activated lysine acetyltransferase Mt-Pat (<xref ref-type="bibr" rid="bib38">Nambi et al., 2013</xref>). Activated Mt-Pat acetylates/propionylates multiple enzymes involved in fatty acid catabolism, including ten FadD paralogs and acetyl-CoA synthetase, thereby inhibiting AMP-ligase activity and oxidation of fatty acids to acetyl-CoA. Inactivation of Mt-Pat, like <italic>macE</italic>, makes Mtb more sensitive to fatty acids (<xref ref-type="bibr" rid="bib38">Nambi et al., 2013</xref>; <xref ref-type="bibr" rid="bib48">Rittershaus et al., 2018</xref>), although the fatty acid sensitivity phenotype is more severe for loss of <italic>macE</italic> as evidenced by the non-essentiality of Mt-Pat under standard laboratory culture conditions (<xref ref-type="bibr" rid="bib13">DeJesus et al., 2017</xref>). Further linking cAMP and fatty acid metabolism, VanderVen and colleagues showed that transposon mutants in <italic>rv1339</italic> showed reduced uptake of BODIPY-palmitate in infected macrophages (<xref ref-type="bibr" rid="bib40">Nazarova et al., 2019</xref>). Collectively, growing evidence suggests that reduced cAMP levels lead to overactive fatty acid catabolism.</p><p>In a series of related findings, Sassetti and colleagues screened Mtb transposon mutant libraries and identified Mt-Pat mutants as strongly attenuated under hypoxia (<xref ref-type="bibr" rid="bib48">Rittershaus et al., 2018</xref>). In the absence of Mt-Pat, it was hypothesized that Mtb fails to downregulate fatty acid catabolism under hypoxic conditions, leading to a continual flux of acetyl-CoA through oxidative TCA metabolism. Consistent with this interpretation, the same screen identified that transposon mutants in the Mce1 transporter promoted fitness in hypoxia. Under hypoxia, the TCA cycle is thought to preferentially work in the reductive direction to regenerate NAD and prevent the accumulation of NADH in the absence of a terminal electron acceptor (<xref ref-type="bibr" rid="bib15">Eoh and Rhee, 2013</xref>; <xref ref-type="bibr" rid="bib59">Watanabe et al., 2011</xref>). As both the oxidative branch of the TCA cycle and fatty acid β-oxidation produce NADH, Δ<italic>mt-pat</italic> under hypoxic conditions becomes redox imbalanced and depletes NAD. Also potentially consistent with this interpretation, re-analysis of the hypoxia TnSeq data identifies <italic>rv1339</italic> as the top resistance-promoting hit (<xref ref-type="bibr" rid="bib48">Rittershaus et al., 2018</xref>). Elevated cAMP levels in <italic>rv1339</italic> transposon mutants could augment Mt-Pat activity and reduce fatty acid uptake and catabolism and drive expression of malate dehydrogenase (<xref ref-type="bibr" rid="bib20">Gazdik and McDonough, 2005</xref>), an enzyme critical for the reductive TCA cycle under hypoxia (<xref ref-type="bibr" rid="bib48">Rittershaus et al., 2018</xref>).</p><p>Finally, recent observations suggest a link between cAMP and the electron transport chain. Isolation of spontaneous resistant mutants to a series of novel inhibitors of the QcrB subunit of the cytochrome <italic>bc<sub>1</sub>-aa<sub>3</sub></italic> oxidase repeatedly identifies mutations in <italic>rv1339</italic> (<xref ref-type="bibr" rid="bib12">Chandrasekera et al., 2017</xref>; <xref ref-type="bibr" rid="bib43">O’Malley et al., 2018</xref>; <xref ref-type="bibr" rid="bib51">Shelton et al., 2021</xref>). How loss of <italic>rv1339</italic> and elevated cAMP promotes resistance to QcrB inhibitors remains to be defined, but in principle could be achieved by elevated cAMP levels increasing electron transport chain activity, for example by increasing expression of the alternative terminal oxidase cytochrome <italic>bd</italic> (<xref ref-type="bibr" rid="bib25">Ko and Oh, 2020</xref>). Indeed, Δ<italic>macE</italic> shows hypersensitivity to the QcrB inhibitor Q203 (<xref ref-type="fig" rid="fig5s7">Figure 5—figure supplement 7</xref>), potentially suggesting a cytochrome <italic>bd</italic> defect in this strain.</p><p>Collectively, ours and published results lead to the following working model (<xref ref-type="fig" rid="fig5">Figure 5J</xref>). Loss of <italic>macE</italic> reduces cAMP levels which reduces the activity of multiple cAMP effectors, including Mt-Pat. That no single annotated or predicted cAMP effector individually recapitulates the phenotypes observed with <italic>macE</italic> indicates that the physiological effects of reduced cAMP levels in Δ<italic>macE</italic> are the consequence of the altered activity of multiple effectors (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Potential downstream cAMP effector proteins include transcription factors like CRP, transporters, phospholipases, and others (<xref ref-type="bibr" rid="bib22">Johnson and McDonough, 2018</xref>), highlighting the potential pleiotropic consequences of modulating cAMP levels. Reduced activity of cAMP-responsive proteins, including Mt-Pat, may increase fatty acid uptake and catabolism (<xref ref-type="bibr" rid="bib40">Nazarova et al., 2019</xref>) and oxidative TCA metabolism while simultaneously reducing electron transport chain activity (<xref ref-type="bibr" rid="bib25">Ko and Oh, 2020</xref>). This derangement may ultimately lead to redox imbalance, perturbed membrane potential, reduced growth, and increased sensitivity to antibiotics through yet-to-be-defined mechanisms.</p><p>Much work remains to be done to test the predictions generated by this model. The lack of changes in Mce1 protein abundance (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>) despite increased fatty acid uptake in low cAMP strains may indicate complex regulation of fatty acid uptake, including post-translational modifications or activity-modulating accessory proteins of the Mce1 transporter. Moreover, it is known that host-associated signals like low pH can activate Mtb adenylate cyclases and that macrophage infection results in a burst of bacterial cAMP production (<xref ref-type="bibr" rid="bib4">Bai et al., 2009</xref>; <xref ref-type="bibr" rid="bib56">Tews et al., 2005</xref>). Thus, it is likely that some of the up to 14–15 additional adenylate cyclases encoded in the Mtb genome are active in the diverse niches encountered by Mtb during infection. Whether cAMP produced under these diverse host-associated conditions also coordinates fatty acid metabolism and intrinsic multidrug resistance remains to be investigated. It is interesting to note that both <italic>macE</italic> and <italic>rv1339</italic> were recently found to be under positive selection (<xref ref-type="bibr" rid="bib35">Liu et al., 2022</xref>), raising the possibility that alterations in cAMP levels are being positively selected in Mtb clinical isolates.</p><p>Notably, the canonical cAMP phosphodiesterase <italic>rv0805</italic> was not identified as a suppressor of palmitic acid toxicity in the Δ<italic>macE</italic> suppressor screen nor in the hypoxia TnSeq screen (<xref ref-type="bibr" rid="bib48">Rittershaus et al., 2018</xref>). Rv0805 is 150 times more active against 2’,3’-cAMP, a cAMP species associated with RNA degradation, than 3’,5’-cAMP, the product of adenylate cyclases (<xref ref-type="bibr" rid="bib24">Keppetipola and Shuman, 2008</xref>). Consistent with these data, overexpression of Rv0805 showed only a modest (~40%) reduction in 3’,5’-cAMP in Mtb (<xref ref-type="bibr" rid="bib2">Agarwal et al., 2009</xref>). Lastly, <italic>rv0805</italic> has a limited phylogenetic distribution and is not found in <italic>M. smegmatis</italic>, which also encodes numerous adenylate cyclases. Thus, it appears that <italic>rv1339</italic> and not <italic>rv0805</italic> is the major 3’,5’-cAMP phosphodiesterase in Mtb (<xref ref-type="bibr" rid="bib57">Thomson et al., 2022</xref>).</p><p>We show here that the sole in vitro essential adenylate cyclase in H37Rv, MacE, links fatty acid metabolism and intrinsic multidrug resistance through the production of cAMP. The adenylate cyclase Rv1625c has recently been shown to be important for cholesterol catabolism, although interestingly this phenotype was independent of the Rv1625c cyclase homology domain (<xref ref-type="bibr" rid="bib60">Wilburn et al., 2022</xref>). In a screen for compounds that disrupt cholesterol catabolism, VanderVen and colleagues discovered V-59, an Rv1625c agonist analogous to the eukaryotic adenylate cyclase activator forskolin (<xref ref-type="bibr" rid="bib58">VanderVen et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Wilburn et al., 2022</xref>). V-59 results in constitutive activation of Rv1625c and cAMP production and, for reasons yet unknown, blocks cholesterol catabolism. Thus, it would appear proper metabolic function of Mtb grown on fatty acids and cholesterol requires ‘just the right amount’ of cAMP: too little and Mtb cannot grow in the presence of fatty acids, too much and Mtb cannot catabolize cholesterol. Moreover, our results and those investigating combination drug treatment with V-59 (<xref ref-type="bibr" rid="bib60">Wilburn et al., 2022</xref>) suggest that deficient or elevated cAMP production may potentiate combination drug therapy.</p><p>Interestingly, whereas cAMP promotes intrinsic multidrug resistance in Mtb, this relationship may not be conserved or in some cases may even be reversed in other bacteria. Large-scale chemical genomic screening of cAMP-deficient Δ<italic>cya E. coli</italic> did not identify any significant differences in antibiotic susceptibility (<xref ref-type="bibr" rid="bib41">Nichols et al., 2011</xref>), although earlier studies found that Δ<italic>cya</italic> in <italic>E. coli</italic> and <italic>S. typhimurium</italic> promotes fosfomycin resistance by reducing expression of the GlpT and UhpT uptake systems (<xref ref-type="bibr" rid="bib53">Shiver et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">Silver, 2017</xref>). In uropathogenic <italic>E. coli</italic>, cAMP was also found to be a negative regulator of persistence (<xref ref-type="bibr" rid="bib36">Molina-Quiroz et al., 2018</xref>). Δ<italic>cya</italic> upregulated the oxidative stress response and SOS-dependent DNA damage repair and promoted survival to beta-lactam antibiotics. Thus, it will be interesting to examine the relationship between cAMP and drug efficacy across diverse bacterial species.</p><p>cAMP is a ubiquitous but poorly understood second messenger in Mtb. Mtb devotes a considerable amount of coding capacity to produce, sense, and degrade cAMP. Here, we reveal the adenylate cyclase MacE as the dominant source of cAMP under standard laboratory growth conditions. cAMP levels are coordinately regulated by MacE and the atypical phosphodiesterase Rv1339. cAMP produced by MacE is critical for Mtb growth on long-chain fatty acids, a host-relevant carbon source, and for intrinsic multidrug resistance, highlighting the potential utility of small molecule modulators of this second messenger to control Mtb infection (<xref ref-type="bibr" rid="bib60">Wilburn et al., 2022</xref>).</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Bacterial strains</title><p>Mtb strains are derivatives of H37Rv, unless indicated as HN878. <italic>E. coli</italic> strains are derivatives of DH5alpha (NEB). <italic>M. smegmatis</italic> strains are derivatives of mc<sup>2</sup>155 <italic>groEL1</italic>Δ<italic>C</italic> (<xref ref-type="bibr" rid="bib42">Noens et al., 2011</xref>). Resources used to construct bacterial strains are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-2"><title>Mycobacterial cultures</title><p>Mtb was grown at 37 °C in Difco Middlebrook 7H9 broth or on 7H10 agar supplemented with 0.2% glycerol (7H9) or 0.5% glycerol (7H10), 0.05% Tween-80, 1x oleic acid-albumin-dextrose-catalase (OADC) and the appropriate antibiotics, unless otherwise specified. Media for the Δ<italic>macE</italic> strain and strains to be tested for fatty acid sensitivity or fatty acid-dependent phenotypes were similarly prepared except 0.05% tyloxapol was used instead of Tween-80, and fatty acid-free albumin-dextrose-catalase (ADC) was used instead of OADC. Where required, antibiotics or small molecules were used at the following concentrations: kanamycin at 20 μg/mL; anhydrotetracycline (ATc) at 100 ng/mL, hygromycin at 50 μg/mL, zeocin at 20 μg/mL, and V-59 at 10 µM. Mtb cultures were grown standing in tissue culture flasks (unless otherwise indicated) at 37 °C, 5% CO<sub>2</sub>. Fatty acid sensitivity testing on 7H10 agar was conducted with 500 μM oleic acid or 200 μM palmitic acid.</p><p><italic>M. smegmatis</italic> was grown at 37 °C in similarly supplemented 7H9 broth or 7H10 agar except ADC was used instead of OADC.</p></sec><sec id="s4-3"><title>Total RNA extraction and RNA-seq</title><p>Triplicate cultures were grown to mid-log phase in 7H9-ADC and diluted back to OD<sub>600</sub> 0.2 in 7H9-OADC. Cultures were incubated for 48 hr. Total RNA extraction was performed as previously described (<xref ref-type="bibr" rid="bib8">Bosch et al., 2021</xref>). Briefly, 2 OD<sub>600</sub> units of bacteria were added to an equivalent volume of GTC buffer (5  M guanidinium thiocyanate, 0.5% sodium N-lauryl sarcosine, 25  mM trisodium citrate dihydrate, and 0.1  M 2-mercaptoethanol), pelleted by centrifugation, resuspended in 1  mL TRIzol (Thermo Fisher 15596026) and lysed by zirconium bead beating (MP Biomedicals 116911050). Chloroform (0.2  ml) was added to each sample and samples were frozen at −80 °C. After thawing, samples were centrifuged to separate phases and the aqueous phase was purified by Direct-zol RNA miniprep (Zymo Research R2052). Residual genomic DNA was removed by TURBO DNase treatment (Invitrogen Ambion AM2238). RNA was purified and concentrated (Zymo Research R1017) and sent to SeqCenter (Pittsburgh, PA, USA) for library preparation. Samples were DNAse treated with Invitrogen DNAse (RNAse free). Library preparation was performed using Illumina’s Stranded Total RNA Prep Ligation with Ribo-Zero Plus kit and 10 bp IDT for Illumina indices. Sequencing was done on a NextSeq2000 giving 2 × 51 bp reads. Demultiplexing, quality control, and adapter trimming were performed with bcl-convert (v3.9.3).</p></sec><sec id="s4-4"><title>Processing and analysis of RNA-seq data</title><p>Raw FASTQ files were aligned to the H37Rv genome (NC_018143.2) using Rsubread (version 2.0.1)(<xref ref-type="bibr" rid="bib33">Liao et al., 2019</xref>) with default settings. Transcript abundances were calculated by processing the resulting BAM files with the summarizeOverlaps function of the R package GenomicAlignments (version 1.22.1) (<xref ref-type="bibr" rid="bib28">Lawrence et al., 2013</xref>). Overlaps were calculated in the ‘Union’ mode, ensuring reads were counted only if they overlap a portion of a single gene/feature. 16 S, 23 S, and 5 S rRNA features (RVBD6018, 6019, and 6020, respectively) were manually removed from the count data to prevent confounding downstream differential gene expression analysis. Reads per kilobase of transcript, per million reads mapped (RPKM) determined for each gene by normalizing transcript abundance to gene length.</p></sec><sec id="s4-5"><title>Domain prediction</title><p>MacE domain prediction was conducted using the Conserved Domain Database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi">https://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi</ext-link>). Transmembrane helices were predicted using TMHMM (<ext-link ext-link-type="uri" xlink:href="https://services.healthtech.dtu.dk/service.php?TMHMM">https://services.healthtech.dtu.dk/service.php?TMHMM</ext-link>-2.0).</p></sec><sec id="s4-6"><title>Antibacterial activity and fatty acid sensitivity measurements</title><p>All antibiotics were dissolved in DMSO (VWR V0231) and dispensed using an HP D300e Digital Dispenser in a 384-well plate format. DMSO did not exceed 1% of the final culture volume and was maintained at the same concentration across all samples. CRISPRi strains were growth-synchronized and pre-depleted in the presence of ATc (100 ng/mL) for 4 days prior to assay for MIC analysis. Cultures were then back diluted to a starting OD<sub>600</sub> of 0.05 in 7H9-OADC, and 50 µL of cell suspension was plated in technical triplicate in wells containing the test compound and fresh ATc (100 ng/mL). Δ<italic>macE</italic> strains were cultured in 7H9-ADC prior to back diluting in 7H9-OADC to seeding a 384-well plate. Similarly, for strains used in antibacterial activity testing in the presence or absence of fatty acids, strains were grown in 7H9-ADC before back-diluting the culture to a starting OD<sub>600</sub> of 0.05 in 7H9-ADC or 7H9-OADC to seed a 384-well plate. Plates were incubated at 37 °C with 5% CO<sub>2</sub>. OD<sub>600</sub> was evaluated using a Tecan Spark plate reader at 14–18 days post-plating and percent growth was calculated relative to the vehicle control for each strain. IC<sub>50</sub> measurements were calculated using a non-linear fit in GraphPad Prism.</p><p>For fatty acid sensitivity measurements, fatty acids were dissolved in 1:1 tyloxapol:ethanol and then diluted at 2x the maximum testing concentration in 7H9-ADC. 2-fold serial dilutions were prepared and 25 μL of each concentration was transferred to a 384-well plate. Cultures were grown to OD<sub>600</sub> 0.4–0.6. Cultures were then back diluted to a starting OD<sub>600</sub> of 0.1 and 25 µL of cell suspension was plated in technical triplicate in wells containing 25 μL of the fatty acid dilution series (and fresh ATc (100 ng/mL), where applicable).</p><p>To quantify growth phenotypes on 7H10 agar, 10-fold serial dilutions of OD-synchronized Mtb cultures were spotted on 7H10-ADC agar containing fatty acids at the indicated concentrations. Where applicable, ATc was added at 100 ng/mL. Plates were incubated at 37 °C and imaged after two weeks.</p></sec><sec id="s4-7"><title>Cell wall permeability assay</title><p>Cell envelope permeability was determined using the ethidium bromide (EtBr) uptake assay as previously described (<xref ref-type="bibr" rid="bib62">Xu et al., 2017</xref>). Briefly, mid-log-phase Mtb cultures were washed once in PBS +0.05% Tween-80 (PBST) and adjusted to OD<sub>600</sub> 0.8 in PBST supplemented with 0.4% glucose. 100 µL of bacterial suspension was added to a black 96-well clear-bottomed plate (Costar). After this, 100 μL of 8 μg/mL EtBr in PBST supplemented with 0.4% glucose was added to each well. EtBr fluorescence was measured (excitation: 530 nm/emission: 590 nm) at 1 min intervals over a course of 90 min. EtBr fluorescence at 30 min is plotted, and normalized to optical density. Experiments were performed in technical triplicate. Similar uptake assays were performed with Calcein-AM (Invitrogen, #C3099) and BCECF-AM (Invitrogen #B1150) with the following changes (1) Calcein-AM and BCECF-AM were assayed at a final concentration of 1 μg/mL. (2) Calcein fluorescence was measured with the following parameters (excitation: 495 nm/emission: 520 nm) (3) BCECF fluorescence was measured with the following parameters (excitation: 490 nm/emission: 530 nm). Plotting and normalization were performed similarly to EtBr.</p><p>A similar assay was performed to determine envelope permeability to a fluorescent vancomycin analog, except that: (1) the bacterial suspension was adjusted at OD<sub>600</sub> = 0.4 in PBS supplemented with 0.4% glucose; (2) cells were incubated with 2 μg/mL BODIPY FL Vancomycin (Thermo Scientific, V34850) for 30 min; (3) 900 μL sample aliquots were taken at different time points, washed twice with PBS, resuspended in 600 μL PBS, and three aliquots of 200 uL each were transferred to a black 96-well clear-bottomed plate (Costar); and (4) fluorescence was measured (excitation: 485 nm/emission: 538 nm) and normalized to the OD<sub>600</sub> of the final bacterial suspension.</p></sec><sec id="s4-8"><title>Vancomycin time-kill kinetic assay</title><p>CRISPRi strains were growth-synchronized and pre-depleted in the presence of ATc (100 ng/mL) for 4 days prior to assay for kill kinetic analysis. Cultures were then back diluted to a starting OD<sub>600</sub> of 0.1 in 7H9-OADC with 1.16 µM vancomycin, 100 ng/mL ATc, and incubated at 37 °C for 96 hr. Bacterial counts for each strain were determined at 0, 0.5, 6, 24, and 96 hr post-antibiotic exposure by plating serial 10-fold dilutions of each culture on 7H10-ADC. Colonies were counted after 17 days of incubation at 37 °C.</p></sec><sec id="s4-9"><title>Measuring drug uptake by mass-spectrometry</title><p>CRISPRi strains were growth-synchronized and pre-depleted in the presence of ATc (100 ng/mL) for 4 days. Growth in 7H9-OADC ATc media proceeded to an OD of 0.8–1.0. One OD unit was used to seed filters for growth on 7H10-OADC ATc agar plates. After 5 days of growth, bacteria-laden filters were transferred and floated on 7H9-OADC ATc media in a ‘swimming pool’ set up overnight. Filters were then transferred and floated on drug-containing 7H9-OADC ATc swimming pools and incubated for 24 hr. Media was collected from each pool and filter sterilized using 0.22 micron nylon centrifugal filters (Corning). 100 μL of each media sample was added to 400 μL of 1:1 acetonitrile/methanol and centrifuged at 13,000 <italic>g</italic> for 10 min at 4 °C to pellet precipitated protein. Supernatants were transferred into mass spectrometry vials and analyzed using a semi-quantitative LC/MS-based method as described previously (<xref ref-type="bibr" rid="bib46">Planck and Rhee, 2021</xref>). Briefly, samples were separated on a Cogent Diamond Hydride Type C column (Microsolv Technologies). The mobile phase consisted of solvent A (ddH<sub>2</sub>O with 0.2% formic acid) and solvent B (acetonitrile with 0.2% formic acid), and the gradient used was as follows: 0–2 min, 85% B; 3–5 min, 80% B; 6–7 min, 75% B; 8–9 min, 70% B; 10–11.1 min, 50% B; 11.1–14 min 20% B; 14.1–24 min 5% B, followed by a 10 min re-equilibration period at 85% B at a flow rate of 0.4 mL/min. This was achieved using an Agilent 1200 Series liquid chromatography (LC) system coupled to an Agilent 6546 quadrupole time of flight (Q-TOF) mass spectrometer in positive acquisition mode, and 2 μL of the sample were injected for each run. Dynamic mass axis calibration was achieved by continuous infusion of a reference mass solution using an isocratic pump with a 100:1 splitter. Resulting data were analyzed using Agilent MassHunter Qualitative Analysis Navigator software. Relative antibiotic concentrations were determined by quantitation of peak heights using <italic>m/z</italic> of 338.1511 for the linezolid (M+H)<sup>+</sup> ion (RT = 1.3 min) and 724.7224 for the vancomycin (M+2 H)<sup>2+</sup> ion (RT = 8.8 min) with a mass tolerance of +/-30 ppm. To determine uptake, drug levels in bacteria-laden filter swimming pools were compared to levels from control swimming pools incubated with cell-free filters under the same conditions.</p></sec><sec id="s4-10"><title>Generation of individual CRISPRi and CRISPRi-resistant complementation strains</title><p>Individual CRISPRi plasmids were cloned as previously described in <xref ref-type="bibr" rid="bib8">Bosch et al., 2021</xref> using Addgene plasmid #166886. Briefly, the CRISPRi plasmid backbone was digested with BsmBI-v2 (NEB #R0739L) and gel purified. sgRNAs were designed to target the non-template strand of the target gene ORF. For each individual sgRNA, two complementary oligonucleotides with appropriate sticky end overhangs were annealed and ligated (T4 ligase NEB # M0202M) into the BsmBI-digested plasmid backbone. Successful cloning was confirmed by Sanger sequencing.</p><p>Individual CRISPRi plasmids were then electroporated into Mtb. Electrocompetent cells were obtained as described in <xref ref-type="bibr" rid="bib37">Murphy et al., 2015</xref>. Briefly, a WT Mtb culture was expanded to an OD<sub>600</sub> = 0.8–1.0 and pelleted (4000 × g for 10 min). The cell pellet was washed three times in sterile 10% glycerol. The washed bacilli were then resuspended in 10% glycerol in a final volume of 5% of the original culture volume. For each transformation, 100 ng plasmid DNA and 100 μL of electrocompetent mycobacteria were mixed and transferred to a 2 mm electroporation cuvette (Bio-Rad #1652082). Where necessary, 100 ng of plasmid plRL19 (Addgene plasmid #163634) was also added. Electroporation was performed using the Gene Pulser X cell electroporation system (Bio-Rad #1652660) set at 2500 V, 700 Ω, and 25 μF. Bacteria were recovered in 7H9 for 24 hr. After the recovery incubation, cells were plated on 7H10 agar supplemented with the appropriate antibiotic to select for transformants.</p><p>To complement CRISPRi-mediated gene knockdown, synonymous mutations were introduced into the complementing allele at both the protospacer adjacent motif (PAM) and seed sequence (the 8–10 most PAM-proximal bases at the 3’ end of the sgRNA targeting sequence) to prevent sgRNA targeting, as described here (<xref ref-type="bibr" rid="bib61">Wong and Rock, 2021</xref>). Silent mutations were introduced into Gibson assembly oligos to generate these ‘CRISPRi resistant’ (CR) alleles. Complementation alleles were expressed from hsp60 promoters in a Tweety integrating plasmid backbone, as indicated in each figure legend and/or the relevant plasmid maps (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). These alleles were then transformed into the corresponding CRISPRi knockdown strain.</p><p>The full list of sgRNA targeting sequences and complementation plasmids can be found in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-11"><title>Construction of the Δ<italic>macE</italic> and complemented Mtb strains</title><p>Mtb H37Rv gene <italic>rv3645</italic>/<italic>macE</italic> was deleted through homologous recombination using a strain expressing the recombinase RecET (<xref ref-type="bibr" rid="bib37">Murphy et al., 2015</xref>). To induce RecET expression, isovaleronitrile was added at a final concentration of 1 μM to a mid-exponential Mtb culture (optical density 580 nm of approximately 1) for 8 hr after which glycine was added at a final concentration of 2 M, and the culture was incubated overnight. A construct composed of a hygromycin-resistant gene (hygR) flanked by 500  bp upstream and downstream of <italic>macE</italic> was synthesized (GenScript) and electroporated into Mtb expressing the recombinase RecET. A <italic>macE</italic> deletion mutant strain (Δ<italic>macE</italic>) was selected in solid fatty acid-free modified Sauton’s with hygromycin. The plasmid expressing recET (pNitET-SacB-kan) was counter selected by growing the deleted mutant in solid fatty acid-free modified Sauton’s supplemented with sucrose 10%. For complementation of Δ<italic>macE</italic>, we have cloned <italic>macE</italic> under the control of the promoter Phsp60 into a plasmid with a kanamycin-resistant cassette that integrates at the att-L5 site (pMCK-Phsp60-rv3645) and electroporated it into the <italic>macE</italic> deletion mutant. Primers and primers are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-12"><title>Isolation of spontaneous fatty acid toxicity suppressors</title><p>The mutant strain Δ<italic>macE</italic> was grown in fatty acid-free modified Sauton’s minimal medium until stationary phase (<xref ref-type="bibr" rid="bib6">Beites et al., 2019</xref>). Solid fatty acid-free modified Sauton’s minimal medium supplemented with oleic acid at a final concentration of 500 μM was used to select spontaneous mutants in the Δ<italic>macE</italic> genetic background that regained the ability to grow in the presence of oleic acid. We inoculated this medium with 10<sup>7</sup> and 10<sup>8</sup> bacteria and incubated the plates for 4 weeks. Medium not supplemented with oleic acid was used as a viability control. Colonies that grew in the medium supplemented with oleic acid were picked and grown in liquid fatty acid-free modified Sauton’s minimal medium. To validate the isolated rescue mutants, we cultured WT, Δ<italic>macE,</italic> complemented, and rescue mutants in liquid fatty acid-free modified Sauton’s minimal medium supplemented with a concentration of oleic acid restrictive to Δ<italic>macE</italic> growth.</p></sec><sec id="s4-13"><title>Whole genome sequencing</title><p>The genetic identity of Δ<italic>macE</italic> and derived spontaneous suppressor mutants was confirmed by whole genome sequencing (WGS). Genomic DNA (150–200 ng) was sheared and HiSeq sequencing libraries were prepared using the KAPA Hyper Prep Kit (Roche). Libraries were amplified by PCR (10 cycles). 5–10 × 10<sup>6</sup> 50 bp paired-end reads were obtained for each sample on an Illumina HiSeq 2500 using the TruSeq SBS Kit v3 (Illumina). Post-run demultiplexing and adapter removal were performed and FASTQ files were inspected using fastqc (<xref ref-type="bibr" rid="bib3">Andrews, 2010</xref>). Trimmed FASTQ files and the reference genome (M. tuberculosis H37RvCO; NZ_CM001515.1) were aligned using bwa mem (<xref ref-type="bibr" rid="bib30">Li and Durbin, 2010</xref>). Bam files were sorted and merged using SAMtools (<xref ref-type="bibr" rid="bib29">Li et al., 2009</xref>). Read groups were added and bam files were de-duplicated using Picard tools and GATK best-practices were followed for SNP and indel detection (<xref ref-type="bibr" rid="bib14">DePristo et al., 2011</xref>). Gene knockouts and cassette insertions were verified for all strains by direct comparison of reads spanning insertion points to plasmid maps and the genome sequence. Reads coverage data was obtained from the software Integrative Genomics Viewer version 2.5.2 (IGV) (<xref ref-type="bibr" rid="bib49">Robinson et al., 2011</xref>).</p></sec><sec id="s4-14"><title>Construction of a genome-wide crispri library in Δ<italic>macE</italic></title><p>Libraries were constructed as previously described (<xref ref-type="bibr" rid="bib8">Bosch et al., 2021</xref>). Briefly, 37 transformations were performed to generate Δ<italic>macE</italic> RLC12 libraries. For each transformation, 1 μg of RLC12 plasmid DNA was added to 100 μL electrocompetent H37Rv Mtb cells (~1 × 10<sup>10</sup> cells per transformation). The cells:DNA mix was transferred to a 2 mm electroporation cuvette (Bio-Rad #1652082) and electroporated at 2500 kV, 700 ohms, and 25 μF. Each transformation was recovered in 2 mL Sauton’s media supplemented with fatty acid-free ADC, glycerol, and tyloxapol (80 mL total) for 16–24 hr. The recovered cells were harvested at 4000 rpm for 10 min, resuspended in 700 μL remaining media per transformation, and plated on Sauton’s agar supplemented with kanamycin (see Bacterial cultures) in Corning Bioassay dishes (Sigma #CLS431111-16EA). Transformation efficiency was estimated from library titring and indicated &gt;12x average sgRNA coverage of RLC12 was achieved in Δ<italic>macE</italic>.</p><p>After 33 days of outgrowth on plates, transformants were scraped and pooled. Scraped cells were homogenized by two dissociation cycles on a gentleMACS Octo Dissociator (Miltenyi Biotec #130095937) using the RNA_02.01 program and 10 gentleMACS M tubes (Miltenyi Biotec #130093236). The library was further declumped by passaging 10 individual <italic>M. tuberculosis</italic> library aliquots in 10 mL of kanamycin-supplemented Sauton’s in T-25 flasks (Falcon # 08-772-1F) for 10 generations. Final Δ<italic>macE</italic> RLC12 library stocks were obtained after pooling the cultures and passing them through a 10 μm cell strainer (Pluriselect #SKU 43-50010-03). Genomic DNA was extracted from the final Δ<italic>macE</italic> RLC12 library stock and library quality were validated by deep sequencing (see Genomic DNA extraction and library preparation for Illumina sequencing).</p></sec><sec id="s4-15"><title>CRISPRi fatty acid-genetic suppressor screening</title><p>The fatty acid-genetic suppressor screen was initiated by thawing 3 × 1.5 mL aliquots (1 OD<sub>600</sub> unit per aliquot) of the Δ<italic>macE</italic> CRISPRi library and inoculating each aliquot into 8.5 mL 7H9-ADC in a vented tissue culture flask (T-25; Corning #430639). The starting OD<sub>600</sub> of each culture was approximately 0.1. Cultures were expanded to OD<sub>600</sub> = 0.47, pooled, and evenly divided to inoculate 2X90 mL cultures with 7.5 ODU each in tissue culture flasks (T-225; Falcon #353138). Cultures were expanded to OD 0.3, pooled, pelleted, and resuspended in 15 mL 7H9-ADC. 700 μL of the concentrated cells were plated on FA-free 7H10-ADC 25 cm bioassay dishes, or 7H10-ADC with increasing concentrations of palmitic acid (200 μM) in quintuplicate. Bioassay dishes were supplemented with kanamycin at 20 μg/mL and ATc at 100 ng/mL. To titer the library, a 10-fold dilution series of the concentrated cells were plated on petri dishes with FA-free 7H10-ADC with kanamycin at 20 μg/mL. All plates were incubated for 20 days. Library coverage based on titering plates was 4620 X. Colonies from the fatty acid-containing bioassay dishes were scraped, avoiding clustered colonies, into PBS and pelleted. Due to confluent growth in the absence of selection on the fatty acid-free plates, a 3 cm × 25 cm rectangular area was scraped into PBS and cells were pelleted for genomic DNA extraction.</p></sec><sec id="s4-16"><title>Genomic DNA extraction and library preparation for illumina sequencing</title><p>Genomic DNA was isolated from bacterial pellets using the CTAB-lysozyme method as previously described (<xref ref-type="bibr" rid="bib8">Bosch et al., 2021</xref>; <xref ref-type="bibr" rid="bib27">Larsen et al., 2007</xref>). Genomic DNA concentration was quantified by Nanodrop. Next, the sgRNA-encoding region was amplified from 500 ng of genomic DNA using NEBNext Ultra II Q5 master Mix (NEB #M0544L). PCR cycling conditions were: 98 °C for 45 s; 17 cycles of 98 °C for 10 s, 64 °C for 30 s, 65 °C for 20 s; 65 °C for 5 min. Samples were dual-indexed. For dual-indexed samples, each PCR reaction contained a unique indexed forward and reverse primer (0.5 μM each) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Forward primers contain a P5 flow cell attachment sequence, a standard Read1 Illumina sequencing primer binding site, custom stagger sequences to ensure base diversity during Illumina sequencing, and a unique barcode to allow for sample pooling during deep sequencing. Reverse primers contain a P7 flow cell attachment sequence, a standard Read2 Illumina sequencing primer binding site, and unique barcodes to allow for dual-indexed sequencing.</p><p>Following PCR amplification, each ~230 bp amplicon was purified using sparQ PureMag Beads (Quantabio # 95196–060) using double-sided size selection (first 0.75x, then an additional 0.12x for a final 0.87x). Size-selected amplicons were quantified with a Qubit 2.0 Fluorometer (Invitrogen). Amplicon size and purity were quality controlled by visualization on an Agilent 2100 Bioanalyzer (high sensitivity chip; Agilent Technologies #5067–4626). Next, individual PCR amplicons were multiplexed into 10 nM pools and sequenced on an Illumina sequencer according to the manufacturer’s instructions (2.5–5% PhiX spike-in; PhiX Sequencing Control v3; Illumina # FC-110–3001). Samples were run on the Illumina NextSeq 500 platform (Single-Read 1x85 cycles and six i7 index cycles).</p></sec><sec id="s4-17"><title>Western blotting</title><p>For detection of protein expression of MacE alleles, 80 OD<sub>600</sub> units of growth synchronized <italic>M. smegmatis</italic> cultures constitutively expressing <italic>macE</italic> were harvested by centrifugation (4000 × g, 10 min). Cells were washed twice in 40 mL PBS-0.05% Tween80 and resuspended in 600 µL of lysis buffer (50 mM Tris, 150 mM NaCl, pH 7.4) containing a protease inhibitor cocktail (Sigma-Aldrich, #11873580001). Cells were lysed by bead beating in Lysis B Matrix tubes (MP Biomedicals; #116911050) using a Precellys Evolution homogenizer (Bertin Instruments, #P000062-PEVO0-A, 3x10,000 RPM, 30 s intervals, 4 °C). n-Dodecyl-β-D-maltopyranoside (Alfa Aesar, #J66869) was added to a final concentration of 1% and incubated at 4 °C with inversion for 2 hr. The cell lysates were cleared by centrifugation (20,000 x g, 2 min), and a 20 µL aliquot was mixed with 4x Laemmli Sample Buffer (Bio-Rad, #1610747) supplemented with DTT. Samples were separated on a 4–12% Bis-Tris polyacrylamide gel (Invitrogen, #NP0323BOX) in MOPS running buffer, transferred to a nitrocellulose membrane using the TransBlot Turbo Transfer System (Bio-Rad, #1704150), and incubated for 1 hr in blocking buffer (LI-COR, #927–60001). Proteins were probed with anti-RpoB (BioLegend, #663905) and anti-His (GenScript, #A00186) primary antibodies overnight at 4 °C and subsequently detected with fluorescent goat anti-mouse secondary antibodies (Bio-Rad, #12004159).</p><p>For detection of Mce1 proteins, Mtb was cultured at 37 °C in 7H9 containing fatty acid-free albumin-dextrose supplemented with 0.01% glycerol and 0.05% tyloxapol to an OD<sub>600</sub> of 0.6. Harvested cells were fixed with 4% PFA, washed with PBS +0.05% tyloxapol, and whole cell lysates were generated by sonicating the bacteria in 1.0% SDS. Proteins were separated using SDS-PAGE then transferred to a nitrocellulose membrane and probed with mce-specific antibodies or anti-GroEL. Anti-Mce1A, anti-Mce1D, and anti-Mce1E primary antibodies were a generous gift from Christopher Sassetti (<xref ref-type="bibr" rid="bib17">Feltcher et al., 2015</xref>). Generation of anti-MceG antibodies was as described (<xref ref-type="bibr" rid="bib39">Nazarova et al., 2017</xref>). GroEL antibodies were obtained from BEI resources.</p></sec><sec id="s4-18"><title>Measuring nucleotides by mass spectrometry</title><p>Strains were grown to an OD of 0.8–1.0 in 7H9-ADC media. CRISPRi strains were grown for 4 days to an OD of 0.8–1.0 in the presence of ATc (100 ng/mL) to predeplete targets. For CRISPRi strains, ATc was maintained in the media at the same concentration until cells were harvested. One OD unit was used to seed filters for growth on 7H10-ADC agar plates. After 5 days of growth, bacteria-laden filters were transferred and floated on 7H9-ADC media in a ‘swimming pool’ set up overnight. Filters were then transferred and floated on 7H9-OADC swimming pools and incubated for 24 hr. For metabolite extraction, filters were transferred to 1 mL of acetonitrile:methanol:water (2:2:1). Bacteria were disrupted by bead beating six times at 6000 rpm for 30 s at 4 °C (Precellys), and lysates were clarified by centrifugation and filter sterilized as described above. Lysates were transferred into mass spectrometry vials and analyzed using a semi-quantitative LC/MS-based ion pairing method. Briefly, samples were separated on a Zorbax Extend C18 column (Agilent). The mobile phase consisted of solvent A (97:3 water:methanol) and solvent B (100% methanol), both containing 5 mM tributylamine and 5.5 mM acetic acid, and the gradient used was as follows: 0–3.5 min, 0% B; 4–7.5 min, 30% B; 8–15 min, 35% B; 20–24 min, 99% B; 24–24.5 min, 0% B, followed by a 10 min re-equilibration period at 0% B at a flow rate of 0.25 mL/min. This was achieved using an Agilent 1200 Series liquid chromatography (LC) system coupled to an Agilent 6220 accurate mass time of flight (TOF) mass spectrometer in negative acquisition mode, and 5 μL of the sample were injected for each run. Dynamic mass axis calibration was achieved by continuous infusion of a reference mass solution using an isocratic pump with a 100:1 splitter. Resulting data were analyzed using Agilent MassHunter Qualitative Analysis Navigator software. Relative abundances of metabolites were determined by quantitation of peak heights or areas with a mass tolerance of +/-35 ppm. Absolute abundances of cAMP were determined by comparing sample peak heights (using <italic>m/z</italic> of 328.0452 for the cAMP (M-H)<sup>-</sup> ion (RT = 9.0 min)) to a standard curve generated by spiking cAMP (final concentration range 0.015 μM to 3.9 μM) into the mycobacterial lysate. In all cases, ion counts were normalized to residual protein content in the samples, which was measured using a BCA assay (Pierce).</p></sec><sec id="s4-19"><title>Measuring camp by ELISA</title><p>Strains were grown to an OD of 0.8–1.0 in 7H9-ADC media. CRISPRi strains were grown for 5 days to an OD of 0.8–1.0 in the presence of ATc (100 ng/mL) to predeplete targets. For CRISPRi strains, ATc was maintained in the media at the same concentration until cells were harvested. 2.5 OD units were used to inoculate 5 mL cultures of 7H9-ADC or 7H9-OADC. Antibiotics were added to 7H9-OADC at a concentration of 10 nM. After 24 hr of growth, the entire culture was harvested by centrifugation (4000 × g, 10 min). Pellets were washed twice by resuspending in 800 µL cold PBS and centrifugation (15,000 × g, 5 min, 4 °C) before resuspending in 400 µL lysis buffer (50 mM Tris-Cl (pH 8.2), 100 mM NaCl, 10% (v/v) glycerol, 10 mM β-mercaptoethanol, protease inhibitor cocktail (Sigma-Aldrich, #11873580001)). Cells were lysed by three bead beating cycles at 10,000 rpm at 4 °C for 60 s (Precellys), resting on a cooled metal rack for 60 s between each cycle. Beads and debris were centrifuged (15,000 × g, 1 min, 4 °C) before transferring to a new tube for further lysate clarification by centrifugation (15,000 × g, 20 min, 4 °C). This supernatant was filter sterilized. Protein concentrations were quantified by Qubit 2.0 Fluorometer (Invitrogen). 200 µL of 0.2 M HCl was added to 200 µL of sample and heated at 95 °C for 10 min and diluted at least 1:5 for quantification by Direct cAMP ELISA kit with acetylation (Enzo #ADI-900–066 A). Resulting data were analyzed using GraphPad Prism.</p></sec><sec id="s4-20"><title>Lipid uptake assays</title><p>Vented T-25 tissue culture flasks were used to culture Mtb in 7H9 containing fatty acid-free albumin-dextrose supplemented with 0.01% glycerol and 0.05% tyloxapol. Once the bacteria reached the mid-logarithmic growth phase, cells were concentrated in a spent medium to a final OD<sub>600</sub> of 0.7. The bacterial cultures were immediately supplied 1.0 µCi of [1-<sup>14</sup>C]-oleic acid (Perkin Elmer) and were incubated at 37 °C. At the 5, 30, 60, and 120 min time points 1.5 ml of the bacterial samples were removed. Each sample was washed three times with cold PBS containing 0.1% Triton X-100 and 0.1% fatty acid-free BSA to remove surface-bound radiolabel. Following the three washes the bacteria were fixed in 4% paraformaldehyde (PFA) and <sup>14</sup>C incorporation was quantified via scintillation counting. Radioactive counts at each time point were plotted and used for linear regression calculations to determine the rate of lipid uptake. The rates were normalized to wild type and expressed as uptake efficiency (%).</p></sec><sec id="s4-21"><title>Radiorespirometry assays</title><p>Catabolism of fatty acids was assessed by measuring the amount of <sup>14</sup>CO<sub>2</sub> released from [1-<sup>14</sup>C]-oleic acid (Perkin Elmer). Cultures of Mtb were grown in 7H9 containing fatty acid-free albumin-dextrose supplemented with 0.01% glycerol and 0.05% tyloxapol to the mid-logarithmic phase of growth in vented T-25 tissue culture flasks. Cultures were then concentrated in spent medium to an OD<sub>600</sub> of 0.5 and 1.0 μCi of radiolabeled lipid was added to each flask. Flasks were individually sealed in an air-tight container along with an open vial containing 0.5 ml of 1 M NaOH. After 5 hr of incubation at 37 °C, the NaOH was neutralized with 0.5 ml of 1 M HCl and the amount of Na<sub>2</sub><sup>14</sup>CO<sub>3</sub> present was quantified via scintillation counting. Values were expressed as %CO<sub>2</sub> release relative to the radioactive counts for the wild type.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Formal analysis, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Resources, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Resources, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Software, Formal analysis, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Supervision, Funding acquisition, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Supervision, Funding acquisition, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Spreadsheet of plasmids, sgRNAs, and primers used in this work.</title></caption><media xlink:href="elife-81177-supp1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-81177-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>RNA-seq data of Mtb H37Rv are deposited in NCBI's Sequence Read Archive (SRA) under BioProject PRJNA930437. Whole genome sequencing data for Δ<italic>macE</italic> and derived spontaneous rescue mutants were deposited in NCBI's SRA under BioProject PRJNA811534. CRISPRi suppressor screen sequencing data was deposited in NCBI's SRA under BioProject PRJNA814682.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>AI</given-names></name><name><surname>Rock</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Rv3645 palmitic acid CRISPRi suppressor screen</data-title><source>NCBI BioProject</source><pub-id pub-id-type="accession" xlink:href="http://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA814682">PRJNA814682</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Beites</surname><given-names>T</given-names></name><name><surname>Schnappinger</surname><given-names>D</given-names></name><name><surname>Ehrt</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Mycobacterium tuberculosis rv3645 knockout</data-title><source>NCBI BioProject</source><pub-id pub-id-type="accession" xlink:href="http://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA811534">PRJNA811534</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>AI</given-names></name><name><surname>Rock</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>WT Mtb H37Rv RNA-seq</data-title><source>NCBI BioProject</source><pub-id pub-id-type="accession" xlink:href="http://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA930437">PRJNA930437</pub-id></element-citation></p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset4"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Poulton</surname><given-names>NC</given-names></name><name><surname>DeJesus</surname><given-names>MA</given-names></name><name><surname>Rock</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Large scale chemical-genetic CRISPRi screen in Mycobacterium tuberculosis</data-title><source>NCBI BioProject</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA738381">PRJNA738381</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Michael Berney and members of the Rock Lab for comments on the manuscript and/or helpful discussions. We thank Christopher Sassetti for the Mce1 antibodies. We thank Bob Mackie for his influence on camp art and fashion, which inspired the name 'MacE' for Rv3645. This work was supported by the Bill and Melinda Gates Foundation (INV-004709, KYR), the NIH (P01AI143575, SE, DS; R01130018, BCV), a joint NIH tuberculosis research units network (TBRU-N) grant (U19AI162584, JMR, KYR), the Department of Defense (PR192421, J.M.R.), the Robertson Therapeutic Development Fund (JMR), and an NIH/NIAID New Innovator Award (1DP2AI144850-01, JMR).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel Motaal</surname><given-names>A</given-names></name><name><surname>Tews</surname><given-names>I</given-names></name><name><surname>Schultz</surname><given-names>JE</given-names></name><name><surname>Linder</surname><given-names>JU</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Fatty acid regulation of adenylyl cyclase rv2212 from Mycobacterium tuberculosis H37Rv</article-title><source>The FEBS Journal</source><volume>273</volume><fpage>4219</fpage><lpage>4228</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2006.05420.x</pub-id><pub-id pub-id-type="pmid">16925585</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>N</given-names></name><name><surname>Lamichhane</surname><given-names>G</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Nolan</surname><given-names>S</given-names></name><name><surname>Bishai</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase</article-title><source>Nature</source><volume>460</volume><fpage>98</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1038/nature08123</pub-id><pub-id pub-id-type="pmid">19516256</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><data-title>FastQC: A quality control tool for high throughput sequence data</data-title><source>FastQC</source><ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>G</given-names></name><name><surname>Schaak</surname><given-names>DD</given-names></name><name><surname>McDonough</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Camp levels within Mycobacterium tuberculosis and Mycobacterium bovis BCG increase upon infection of macrophages</article-title><source>FEMS Immunology and Medical Microbiology</source><volume>55</volume><fpage>68</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.2008.00500.x</pub-id><pub-id pub-id-type="pmid">19076221</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batt</surname><given-names>SM</given-names></name><name><surname>Minnikin</surname><given-names>DE</given-names></name><name><surname>Besra</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The thick waxy coat of mycobacteria, a protective layer against antibiotics and the host’s immune system</article-title><source>The Biochemical Journal</source><volume>477</volume><fpage>1983</fpage><lpage>2006</lpage><pub-id pub-id-type="doi">10.1042/BCJ20200194</pub-id><pub-id pub-id-type="pmid">32470138</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beites</surname><given-names>T</given-names></name><name><surname>O’Brien</surname><given-names>K</given-names></name><name><surname>Tiwari</surname><given-names>D</given-names></name><name><surname>Engelhart</surname><given-names>CA</given-names></name><name><surname>Walters</surname><given-names>S</given-names></name><name><surname>Andrews</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>HJ</given-names></name><name><surname>Sutphen</surname><given-names>ML</given-names></name><name><surname>Weiner</surname><given-names>DM</given-names></name><name><surname>Dayao</surname><given-names>EK</given-names></name><name><surname>Zimmerman</surname><given-names>M</given-names></name><name><surname>Prideaux</surname><given-names>B</given-names></name><name><surname>Desai</surname><given-names>PV</given-names></name><name><surname>Masquelin</surname><given-names>T</given-names></name><name><surname>Via</surname><given-names>LE</given-names></name><name><surname>Dartois</surname><given-names>V</given-names></name><name><surname>Boshoff</surname><given-names>HI</given-names></name><name><surname>Barry</surname><given-names>CE</given-names></name><name><surname>Ehrt</surname><given-names>S</given-names></name><name><surname>Schnappinger</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Plasticity of the mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>4970</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-12956-2</pub-id><pub-id pub-id-type="pmid">31672993</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellerose</surname><given-names>MM</given-names></name><name><surname>Proulx</surname><given-names>MK</given-names></name><name><surname>Smith</surname><given-names>CM</given-names></name><name><surname>Baker</surname><given-names>RE</given-names></name><name><surname>Ioerger</surname><given-names>TR</given-names></name><name><surname>Sassetti</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Distinct bacterial pathways influence the efficacy of antibiotics against mycobacterium tuberculosis</article-title><source>MSystems</source><volume>5</volume><elocation-id>e00396-20</elocation-id><pub-id pub-id-type="doi">10.1128/mSystems.00396-20</pub-id><pub-id pub-id-type="pmid">32753506</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>B</given-names></name><name><surname>DeJesus</surname><given-names>MA</given-names></name><name><surname>Poulton</surname><given-names>NC</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Engelhart</surname><given-names>CA</given-names></name><name><surname>Zaveri</surname><given-names>A</given-names></name><name><surname>Lavalette</surname><given-names>S</given-names></name><name><surname>Ruecker</surname><given-names>N</given-names></name><name><surname>Trujillo</surname><given-names>C</given-names></name><name><surname>Wallach</surname><given-names>JB</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Ehrt</surname><given-names>S</given-names></name><name><surname>Chait</surname><given-names>BT</given-names></name><name><surname>Schnappinger</surname><given-names>D</given-names></name><name><surname>Rock</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Genome-Wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis</article-title><source>Cell</source><volume>184</volume><fpage>4579</fpage><lpage>4592</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.06.033</pub-id><pub-id pub-id-type="pmid">34297925</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boutte</surname><given-names>CC</given-names></name><name><surname>Baer</surname><given-names>CE</given-names></name><name><surname>Papavinasasundaram</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Chase</surname><given-names>MR</given-names></name><name><surname>Meniche</surname><given-names>X</given-names></name><name><surname>Fortune</surname><given-names>SM</given-names></name><name><surname>Sassetti</surname><given-names>CM</given-names></name><name><surname>Ioerger</surname><given-names>TR</given-names></name><name><surname>Rubin</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A cytoplasmic peptidoglycan amidase homologue controls mycobacterial cell wall synthesis</article-title><source>eLife</source><volume>5</volume><elocation-id>e14590</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.14590</pub-id><pub-id pub-id-type="pmid">27304077</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cann</surname><given-names>MJ</given-names></name><name><surname>Hammer</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Kanacher</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>A defined subset of adenylyl cyclases is regulated by bicarbonate ion</article-title><source>The Journal of Biological Chemistry</source><volume>278</volume><fpage>35033</fpage><lpage>35038</lpage><pub-id pub-id-type="doi">10.1074/jbc.M303025200</pub-id><pub-id pub-id-type="pmid">12829712</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carey</surname><given-names>AF</given-names></name><name><surname>Rock</surname><given-names>JM</given-names></name><name><surname>Krieger</surname><given-names>IV</given-names></name><name><surname>Chase</surname><given-names>MR</given-names></name><name><surname>Fernandez-Suarez</surname><given-names>M</given-names></name><name><surname>Gagneux</surname><given-names>S</given-names></name><name><surname>Sacchettini</surname><given-names>JC</given-names></name><name><surname>Ioerger</surname><given-names>TR</given-names></name><name><surname>Fortune</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>TnSeq of mycobacterium tuberculosis clinical isolates reveals strain-specific antibiotic liabilities</article-title><source>PLOS Pathogens</source><volume>14</volume><elocation-id>e1006939</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006939</pub-id><pub-id pub-id-type="pmid">29505613</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandrasekera</surname><given-names>NS</given-names></name><name><surname>Berube</surname><given-names>BJ</given-names></name><name><surname>Shetye</surname><given-names>G</given-names></name><name><surname>Chettiar</surname><given-names>S</given-names></name><name><surname>O’Malley</surname><given-names>T</given-names></name><name><surname>Manning</surname><given-names>A</given-names></name><name><surname>Flint</surname><given-names>L</given-names></name><name><surname>Awasthi</surname><given-names>D</given-names></name><name><surname>Ioerger</surname><given-names>TR</given-names></name><name><surname>Sacchettini</surname><given-names>J</given-names></name><name><surname>Masquelin</surname><given-names>T</given-names></name><name><surname>Hipskind</surname><given-names>PA</given-names></name><name><surname>Odingo</surname><given-names>J</given-names></name><name><surname>Parish</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Improved phenoxyalkylbenzimidazoles with activity against Mycobacterium tuberculosis appear to target qcrb</article-title><source>ACS Infectious Diseases</source><volume>3</volume><fpage>898</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.7b00112</pub-id><pub-id pub-id-type="pmid">29035551</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeJesus</surname><given-names>MA</given-names></name><name><surname>Gerrick</surname><given-names>ER</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Long</surname><given-names>JE</given-names></name><name><surname>Boutte</surname><given-names>CC</given-names></name><name><surname>Rubin</surname><given-names>EJ</given-names></name><name><surname>Schnappinger</surname><given-names>D</given-names></name><name><surname>Ehrt</surname><given-names>S</given-names></name><name><surname>Fortune</surname><given-names>SM</given-names></name><name><surname>Sassetti</surname><given-names>CM</given-names></name><name><surname>Ioerger</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Comprehensive essentiality analysis of the mycobacterium tuberculosis genome via saturating transposon mutagenesis</article-title><source>MBio</source><volume>8</volume><elocation-id>e02133-16</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02133-16</pub-id><pub-id pub-id-type="pmid">28096490</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DePristo</surname><given-names>MA</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Poplin</surname><given-names>R</given-names></name><name><surname>Garimella</surname><given-names>KV</given-names></name><name><surname>Maguire</surname><given-names>JR</given-names></name><name><surname>Hartl</surname><given-names>C</given-names></name><name><surname>Philippakis</surname><given-names>AA</given-names></name><name><surname>del Angel</surname><given-names>G</given-names></name><name><surname>Rivas</surname><given-names>MA</given-names></name><name><surname>Hanna</surname><given-names>M</given-names></name><name><surname>McKenna</surname><given-names>A</given-names></name><name><surname>Fennell</surname><given-names>TJ</given-names></name><name><surname>Kernytsky</surname><given-names>AM</given-names></name><name><surname>Sivachenko</surname><given-names>AY</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A framework for variation discovery and genotyping using next-generation DNA sequencing data</article-title><source>Nature Genetics</source><volume>43</volume><fpage>491</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1038/ng.806</pub-id><pub-id pub-id-type="pmid">21478889</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eoh</surname><given-names>H</given-names></name><name><surname>Rhee</surname><given-names>KY</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in mycobacterium tuberculosis</article-title><source>PNAS</source><volume>110</volume><fpage>6554</fpage><lpage>6559</lpage><pub-id pub-id-type="doi">10.1073/PNAS.1219375110</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eoh</surname><given-names>H</given-names></name><name><surname>Rhee</surname><given-names>KY</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Methylcitrate cycle defines the bactericidal essentiality of isocitrate lyase for survival of mycobacterium tuberculosis on fatty acids</article-title><source>PNAS</source><volume>111</volume><fpage>4976</fpage><lpage>4981</lpage><pub-id pub-id-type="doi">10.1073/pnas.1400390111</pub-id><pub-id pub-id-type="pmid">24639517</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feltcher</surname><given-names>ME</given-names></name><name><surname>Gunawardena</surname><given-names>HP</given-names></name><name><surname>Zulauf</surname><given-names>KE</given-names></name><name><surname>Malik</surname><given-names>S</given-names></name><name><surname>Griffin</surname><given-names>JE</given-names></name><name><surname>Sassetti</surname><given-names>CM</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Braunstein</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Label-free quantitative proteomics reveals a role for the mycobacterium tuberculosis seca2 pathway in exporting solute binding proteins and mce transporters to the cell wall</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>14</volume><fpage>1501</fpage><lpage>1516</lpage><pub-id pub-id-type="doi">10.1074/mcp.M114.044685</pub-id><pub-id pub-id-type="pmid">25813378</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fieweger</surname><given-names>RA</given-names></name><name><surname>Wilburn</surname><given-names>KM</given-names></name><name><surname>Montague</surname><given-names>CR</given-names></name><name><surname>Roszkowski</surname><given-names>EK</given-names></name><name><surname>Kelly</surname><given-names>CM</given-names></name><name><surname>Southard</surname><given-names>TL</given-names></name><name><surname>Sondermann</surname><given-names>H</given-names></name><name><surname>Nazarova</surname><given-names>EV</given-names></name><name><surname>VanderVen</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>MceG stabilizes the mce1 and mce4 transporters in mycobacterium tuberculosis</article-title><source>The Journal of Biological Chemistry</source><volume>299</volume><elocation-id>102910</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2023.102910</pub-id><pub-id pub-id-type="pmid">36642182</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galagan</surname><given-names>JE</given-names></name><name><surname>Minch</surname><given-names>K</given-names></name><name><surname>Peterson</surname><given-names>M</given-names></name><name><surname>Lyubetskaya</surname><given-names>A</given-names></name><name><surname>Azizi</surname><given-names>E</given-names></name><name><surname>Sweet</surname><given-names>L</given-names></name><name><surname>Gomes</surname><given-names>A</given-names></name><name><surname>Rustad</surname><given-names>T</given-names></name><name><surname>Dolganov</surname><given-names>G</given-names></name><name><surname>Glotova</surname><given-names>I</given-names></name><name><surname>Abeel</surname><given-names>T</given-names></name><name><surname>Mahwinney</surname><given-names>C</given-names></name><name><surname>Kennedy</surname><given-names>AD</given-names></name><name><surname>Allard</surname><given-names>R</given-names></name><name><surname>Brabant</surname><given-names>W</given-names></name><name><surname>Krueger</surname><given-names>A</given-names></name><name><surname>Jaini</surname><given-names>S</given-names></name><name><surname>Honda</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>W-H</given-names></name><name><surname>Hickey</surname><given-names>MJ</given-names></name><name><surname>Zucker</surname><given-names>J</given-names></name><name><surname>Garay</surname><given-names>C</given-names></name><name><surname>Weiner</surname><given-names>B</given-names></name><name><surname>Sisk</surname><given-names>P</given-names></name><name><surname>Stolte</surname><given-names>C</given-names></name><name><surname>Winkler</surname><given-names>JK</given-names></name><name><surname>Van de Peer</surname><given-names>Y</given-names></name><name><surname>Iazzetti</surname><given-names>P</given-names></name><name><surname>Camacho</surname><given-names>D</given-names></name><name><surname>Dreyfuss</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Dorhoi</surname><given-names>A</given-names></name><name><surname>Mollenkopf</surname><given-names>H-J</given-names></name><name><surname>Drogaris</surname><given-names>P</given-names></name><name><surname>Lamontagne</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Piquenot</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>ST</given-names></name><name><surname>Raman</surname><given-names>S</given-names></name><name><surname>Kaufmann</surname><given-names>SHE</given-names></name><name><surname>Mohney</surname><given-names>RP</given-names></name><name><surname>Chelsky</surname><given-names>D</given-names></name><name><surname>Moody</surname><given-names>DB</given-names></name><name><surname>Sherman</surname><given-names>DR</given-names></name><name><surname>Schoolnik</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The mycobacterium tuberculosis regulatory network and hypoxia</article-title><source>Nature</source><volume>499</volume><fpage>178</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1038/nature12337</pub-id><pub-id pub-id-type="pmid">23823726</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gazdik</surname><given-names>MA</given-names></name><name><surname>McDonough</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Identification of cyclic AMP-regulated genes in mycobacterium tuberculosis complex bacteria under low-oxygen conditions</article-title><source>Journal of Bacteriology</source><volume>187</volume><fpage>2681</fpage><lpage>2692</lpage><pub-id pub-id-type="doi">10.1128/JB.187.8.2681-2692.2005</pub-id><pub-id pub-id-type="pmid">15805514</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulko</surname><given-names>M</given-names></name><name><surname>Berndt</surname><given-names>F</given-names></name><name><surname>Gruber</surname><given-names>M</given-names></name><name><surname>Linder</surname><given-names>JU</given-names></name><name><surname>Truffault</surname><given-names>V</given-names></name><name><surname>Schultz</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Schultz</surname><given-names>JE</given-names></name><name><surname>Lupas</surname><given-names>AN</given-names></name><name><surname>Coles</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The HAMP domain structure implies helix rotation in transmembrane signaling</article-title><source>Cell</source><volume>126</volume><fpage>929</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.06.058</pub-id><pub-id pub-id-type="pmid">16959572</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>RM</given-names></name><name><surname>McDonough</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cyclic nucleotide signaling in mycobacterium tuberculosis: An expanding repertoire</article-title><source>Pathogens and Disease</source><volume>76</volume><elocation-id>fty048</elocation-id><pub-id pub-id-type="doi">10.1093/femspd/fty048</pub-id><pub-id pub-id-type="pmid">29905867</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kengmo Tchoupa</surname><given-names>A</given-names></name><name><surname>Eijkelkamp</surname><given-names>BA</given-names></name><name><surname>Peschel</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Bacterial adaptation strategies to host-derived fatty acids</article-title><source>Trends in Microbiology</source><volume>30</volume><fpage>241</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2021.06.002</pub-id><pub-id pub-id-type="pmid">34218980</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keppetipola</surname><given-names>N</given-names></name><name><surname>Shuman</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A phosphate-binding histidine of binuclear metallophosphodiesterase enzymes is a determinant of 2’,3’-cyclic nucleotide phosphodiesterase activity</article-title><source>The Journal of Biological Chemistry</source><volume>283</volume><fpage>30942</fpage><lpage>30949</lpage><pub-id pub-id-type="doi">10.1074/jbc.M805064200</pub-id><pub-id pub-id-type="pmid">18757371</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>E-M</given-names></name><name><surname>Oh</surname><given-names>J-I</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Induction of the cydab operon encoding the BD quinol oxidase under respiration-inhibitory conditions by the major cAMP receptor protein msmeg_6189 in Mycobacterium smegmatis</article-title><source>Frontiers in Microbiology</source><volume>11</volume><elocation-id>608624</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2020.608624</pub-id><pub-id pub-id-type="pmid">33343552</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larrouy-Maumus</surname><given-names>G</given-names></name><name><surname>Marino</surname><given-names>LB</given-names></name><name><surname>Madduri</surname><given-names>AVR</given-names></name><name><surname>Ragan</surname><given-names>TJ</given-names></name><name><surname>Hunt</surname><given-names>DM</given-names></name><name><surname>Bassano</surname><given-names>L</given-names></name><name><surname>Gutierrez</surname><given-names>MG</given-names></name><name><surname>Moody</surname><given-names>DB</given-names></name><name><surname>Pavan</surname><given-names>FR</given-names></name><name><surname>de Carvalho</surname><given-names>LPS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cell-envelope remodeling as a determinant of phenotypic antibacterial tolerance in <italic>mycobacterium tuberculosis</italic></article-title><source>ACS Infectious Diseases</source><volume>2</volume><fpage>352</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.5b00148</pub-id><pub-id pub-id-type="pmid">27231718</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>MH</given-names></name><name><surname>Biermann</surname><given-names>K</given-names></name><name><surname>Tandberg</surname><given-names>S</given-names></name><name><surname>Hsu</surname><given-names>T</given-names></name><name><surname>Jacobs</surname><given-names>WRJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Genetic manipulation of mycobacterium tuberculosis</article-title><source>Current Protocols in Microbiology</source><volume>10</volume><elocation-id>Unit 10A.2</elocation-id><pub-id pub-id-type="doi">10.1002/9780471729259.mc10a02s6</pub-id><pub-id pub-id-type="pmid">18770603</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>M</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Pagès</surname><given-names>H</given-names></name><name><surname>Aboyoun</surname><given-names>P</given-names></name><name><surname>Carlson</surname><given-names>M</given-names></name><name><surname>Gentleman</surname><given-names>R</given-names></name><name><surname>Morgan</surname><given-names>MT</given-names></name><name><surname>Carey</surname><given-names>VJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Software for computing and annotating genomic ranges</article-title><source>PLOS Computational Biology</source><volume>9</volume><elocation-id>e1003118</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1003118</pub-id><pub-id pub-id-type="pmid">23950696</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Handsaker</surname><given-names>B</given-names></name><name><surname>Wysoker</surname><given-names>A</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Homer</surname><given-names>N</given-names></name><name><surname>Marth</surname><given-names>G</given-names></name><name><surname>Abecasis</surname><given-names>G</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The sequence alignment/map format and samtools</article-title><source>Bioinformatics</source><volume>25</volume><fpage>2078</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Fast and accurate long-read alignment with burrows-wheeler transform</article-title><source>Bioinformatics</source><volume>26</volume><fpage>589</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp698</pub-id><pub-id pub-id-type="pmid">20080505</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Cong</surname><given-names>L</given-names></name><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Liu</surname><given-names>JS</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>MAGeCK enables robust identification of essential genes from genome-scale CRISPR/cas9 knockout screens</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>554</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0554-4</pub-id><pub-id pub-id-type="pmid">25476604</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Poulton</surname><given-names>NC</given-names></name><name><surname>Chang</surname><given-names>JS</given-names></name><name><surname>Azadian</surname><given-names>ZA</given-names></name><name><surname>DeJesus</surname><given-names>MA</given-names></name><name><surname>Ruecker</surname><given-names>N</given-names></name><name><surname>Zimmerman</surname><given-names>MD</given-names></name><name><surname>Eckartt</surname><given-names>KA</given-names></name><name><surname>Bosch</surname><given-names>B</given-names></name><name><surname>Engelhart</surname><given-names>CA</given-names></name><name><surname>Sullivan</surname><given-names>DF</given-names></name><name><surname>Gengenbacher</surname><given-names>M</given-names></name><name><surname>Dartois</surname><given-names>VA</given-names></name><name><surname>Schnappinger</surname><given-names>D</given-names></name><name><surname>Rock</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis</article-title><source>Nature Microbiology</source><volume>7</volume><fpage>766</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1038/s41564-022-01130-y</pub-id><pub-id pub-id-type="pmid">35637331</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The R package rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads</article-title><source>Nucleic Acids Research</source><volume>47</volume><elocation-id>e47</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkz114</pub-id><pub-id pub-id-type="pmid">30783653</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linder</surname><given-names>JU</given-names></name><name><surname>Schultz</surname><given-names>A</given-names></name><name><surname>Schultz</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Adenylyl cyclase Rv1264 from Mycobacterium tuberculosis has an autoinhibitory N-terminal domain</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>15271</fpage><lpage>15276</lpage><pub-id pub-id-type="doi">10.1074/jbc.M200235200</pub-id><pub-id pub-id-type="pmid">11839758</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Dulberger</surname><given-names>CL</given-names></name><name><surname>Stanley</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>ES</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Culviner</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>YJ</given-names></name><name><surname>Hicks</surname><given-names>ND</given-names></name><name><surname>Babunovic</surname><given-names>GH</given-names></name><name><surname>Giffen</surname><given-names>SR</given-names></name><name><surname>Aldridge</surname><given-names>BB</given-names></name><name><surname>Garner</surname><given-names>EC</given-names></name><name><surname>Rubin</surname><given-names>EJ</given-names></name><name><surname>Chao</surname><given-names>MC</given-names></name><name><surname>Fortune</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Tuberculosis Treatment Failure Associated with Evolution of Antibiotic Resilience</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2022.03.29.486233</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molina-Quiroz</surname><given-names>RC</given-names></name><name><surname>Silva-Valenzuela</surname><given-names>C</given-names></name><name><surname>Brewster</surname><given-names>J</given-names></name><name><surname>Castro-Nallar</surname><given-names>E</given-names></name><name><surname>Levy</surname><given-names>SB</given-names></name><name><surname>Camilli</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cyclic AMP regulates bacterial persistence through repression of the oxidative stress response and SOS-dependent DNA repair in uropathogenic <italic>Escherichia coli</italic></article-title><source>MBio</source><volume>9</volume><elocation-id>e02144-17</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02144-17</pub-id><pub-id pub-id-type="pmid">29317513</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>KC</given-names></name><name><surname>Papavinasasundaram</surname><given-names>K</given-names></name><name><surname>Sassetti</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mycobacterial recombineering</article-title><source>Methods in Molecular Biology</source><volume>1285</volume><fpage>177</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2450-9_10</pub-id><pub-id pub-id-type="pmid">25779316</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nambi</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>K</given-names></name><name><surname>Bhattacharyya</surname><given-names>M</given-names></name><name><surname>Ramakrishnan</surname><given-names>P</given-names></name><name><surname>Ravikumar</surname><given-names>V</given-names></name><name><surname>Siddiqui</surname><given-names>N</given-names></name><name><surname>Thomas</surname><given-names>AT</given-names></name><name><surname>Visweswariah</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cyclic AMP-dependent protein lysine acylation in mycobacteria regulates fatty acid and propionate metabolism</article-title><source>The Journal of Biological Chemistry</source><volume>288</volume><fpage>14114</fpage><lpage>14124</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.463992</pub-id><pub-id pub-id-type="pmid">23553634</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazarova</surname><given-names>EV</given-names></name><name><surname>Montague</surname><given-names>CR</given-names></name><name><surname>La</surname><given-names>T</given-names></name><name><surname>Wilburn</surname><given-names>KM</given-names></name><name><surname>Sukumar</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Caldwell</surname><given-names>S</given-names></name><name><surname>Russell</surname><given-names>DG</given-names></name><name><surname>VanderVen</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Rv3723/luca coordinates fatty acid and cholesterol uptake in Mycobacterium tuberculosis</article-title><source>eLife</source><volume>6</volume><elocation-id>e26969</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.26969</pub-id><pub-id pub-id-type="pmid">28708968</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazarova</surname><given-names>EV</given-names></name><name><surname>Montague</surname><given-names>CR</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>La</surname><given-names>T</given-names></name><name><surname>Russell</surname><given-names>D</given-names></name><name><surname>VanderVen</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The genetic requirements of fatty acid import by Mycobacterium tuberculosis within macrophages</article-title><source>eLife</source><volume>8</volume><elocation-id>e43621</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.43621</pub-id><pub-id pub-id-type="pmid">30735132</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>RJ</given-names></name><name><surname>Sen</surname><given-names>S</given-names></name><name><surname>Choo</surname><given-names>YJ</given-names></name><name><surname>Beltrao</surname><given-names>P</given-names></name><name><surname>Zietek</surname><given-names>M</given-names></name><name><surname>Chaba</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Kazmierczak</surname><given-names>KM</given-names></name><name><surname>Lee</surname><given-names>KJ</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Shales</surname><given-names>M</given-names></name><name><surname>Lovett</surname><given-names>S</given-names></name><name><surname>Winkler</surname><given-names>ME</given-names></name><name><surname>Krogan</surname><given-names>NJ</given-names></name><name><surname>Typas</surname><given-names>A</given-names></name><name><surname>Gross</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Phenotypic landscape of a bacterial cell</article-title><source>Cell</source><volume>144</volume><fpage>143</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.11.052</pub-id><pub-id pub-id-type="pmid">21185072</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noens</surname><given-names>EE</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>Anandhakrishnan</surname><given-names>M</given-names></name><name><surname>Poulsen</surname><given-names>C</given-names></name><name><surname>Ehebauer</surname><given-names>MT</given-names></name><name><surname>Wilmanns</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Improved mycobacterial protein production using a mycobacterium smegmatis groel1δC expression strain</article-title><source>BMC Biotechnology</source><volume>11</volume><elocation-id>27</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6750-11-27</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Malley</surname><given-names>T</given-names></name><name><surname>Alling</surname><given-names>T</given-names></name><name><surname>Early</surname><given-names>JV</given-names></name><name><surname>Wescott</surname><given-names>HA</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Moraski</surname><given-names>GC</given-names></name><name><surname>Miller</surname><given-names>MJ</given-names></name><name><surname>Masquelin</surname><given-names>T</given-names></name><name><surname>Hipskind</surname><given-names>PA</given-names></name><name><surname>Parish</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Imidazopyridine compounds inhibit mycobacterial growth by depleting ATP levels</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>62</volume><elocation-id>e02439-17</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.02439-17</pub-id><pub-id pub-id-type="pmid">29632008</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parish</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Two-component regulatory systems of mycobacteria</article-title><source>Microbiology Spectrum</source><volume>2</volume><elocation-id>MGM20010</elocation-id><pub-id pub-id-type="doi">10.1128/microbiolspec.MGM2-0010-2013</pub-id><pub-id pub-id-type="pmid">26082118</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>HD</given-names></name><name><surname>Guinn</surname><given-names>KM</given-names></name><name><surname>Harrell</surname><given-names>MI</given-names></name><name><surname>Liao</surname><given-names>R</given-names></name><name><surname>Voskuil</surname><given-names>MI</given-names></name><name><surname>Tompa</surname><given-names>M</given-names></name><name><surname>Schoolnik</surname><given-names>GK</given-names></name><name><surname>Sherman</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Rv3133c/dosr is a transcription factor that mediates the hypoxic response of mycobacterium tuberculosis</article-title><source>Molecular Microbiology</source><volume>48</volume><fpage>833</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2003.03474.x</pub-id><pub-id pub-id-type="pmid">12694625</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Planck</surname><given-names>KA</given-names></name><name><surname>Rhee</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Metabolomics of mycobacterium tuberculosis</article-title><source>Methods in Molecular Biology</source><volume>2314</volume><fpage>579</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-1460-0_25</pub-id><pub-id pub-id-type="pmid">34235671</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richard-Greenblatt</surname><given-names>M</given-names></name><name><surname>Av-Gay</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Epigenetic phosphorylation control of mycobacterium tuberculosis infection and persistence</article-title><source>Microbiol Spectr</source><volume>5</volume><elocation-id>2015</elocation-id><pub-id pub-id-type="doi">10.1128/MICROBIOLSPEC.TBTB2-0005-2015</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rittershaus</surname><given-names>ESC</given-names></name><name><surname>Baek</surname><given-names>S-H</given-names></name><name><surname>Krieger</surname><given-names>IV</given-names></name><name><surname>Nelson</surname><given-names>SJ</given-names></name><name><surname>Cheng</surname><given-names>Y-S</given-names></name><name><surname>Nambi</surname><given-names>S</given-names></name><name><surname>Baker</surname><given-names>RE</given-names></name><name><surname>Leszyk</surname><given-names>JD</given-names></name><name><surname>Shaffer</surname><given-names>SA</given-names></name><name><surname>Sacchettini</surname><given-names>JC</given-names></name><name><surname>Sassetti</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A lysine acetyltransferase contributes to the metabolic adaptation to hypoxia in mycobacterium tuberculosis</article-title><source>Cell Chemical Biology</source><volume>25</volume><fpage>1495</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2018.09.009</pub-id><pub-id pub-id-type="pmid">30318462</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>JT</given-names></name><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name><name><surname>Winckler</surname><given-names>W</given-names></name><name><surname>Guttman</surname><given-names>M</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Integrative genomics viewer</article-title><source>Nature Biotechnology</source><volume>29</volume><fpage>24</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1038/nbt.1754</pub-id><pub-id pub-id-type="pmid">21221095</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rock</surname><given-names>JM</given-names></name><name><surname>Hopkins</surname><given-names>FF</given-names></name><name><surname>Chavez</surname><given-names>A</given-names></name><name><surname>Diallo</surname><given-names>M</given-names></name><name><surname>Chase</surname><given-names>MR</given-names></name><name><surname>Gerrick</surname><given-names>ER</given-names></name><name><surname>Pritchard</surname><given-names>JR</given-names></name><name><surname>Church</surname><given-names>GM</given-names></name><name><surname>Rubin</surname><given-names>EJ</given-names></name><name><surname>Sassetti</surname><given-names>CM</given-names></name><name><surname>Schnappinger</surname><given-names>D</given-names></name><name><surname>Fortune</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform</article-title><source>Nature Microbiology</source><volume>2</volume><elocation-id>16274</elocation-id><pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.274</pub-id><pub-id pub-id-type="pmid">28165460</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Shelton</surname><given-names>C</given-names></name><name><surname>McNeil</surname><given-names>M</given-names></name><name><surname>Flint</surname><given-names>L</given-names></name><name><surname>Russell</surname><given-names>D</given-names></name><name><surname>Berube</surname><given-names>B</given-names></name><name><surname>Korkegian</surname><given-names>A</given-names></name><name><surname>Ovechkina</surname><given-names>Y</given-names></name><name><surname>Parish</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Triazolopyrimidines Target Aerobic Respiration in Mycobacterium Tuberculosis</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.10.18.464924</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shenoy</surname><given-names>AR</given-names></name><name><surname>Visweswariah</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mycobacterial adenylyl cyclases: Biochemical diversity and structural plasticity</article-title><source>FEBS Letters</source><volume>580</volume><fpage>3344</fpage><lpage>3352</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2006.05.034</pub-id><pub-id pub-id-type="pmid">16730005</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiver</surname><given-names>AL</given-names></name><name><surname>Osadnik</surname><given-names>H</given-names></name><name><surname>Kritikos</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Krogan</surname><given-names>N</given-names></name><name><surname>Typas</surname><given-names>A</given-names></name><name><surname>Gross</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A chemical-genomic screen of neglected antibiotics reveals illicit transport of kasugamycin and blasticidin S</article-title><source>PLOS Genetics</source><volume>12</volume><elocation-id>e1006124</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1006124</pub-id><pub-id pub-id-type="pmid">27355376</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>LL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Fosfomycin: Mechanism and resistance</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>7</volume><elocation-id>a025262</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a025262</pub-id><pub-id pub-id-type="pmid">28062557</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stapleton</surname><given-names>M</given-names></name><name><surname>Haq</surname><given-names>I</given-names></name><name><surname>Hunt</surname><given-names>DM</given-names></name><name><surname>Arnvig</surname><given-names>KB</given-names></name><name><surname>Artymiuk</surname><given-names>PJ</given-names></name><name><surname>Buxton</surname><given-names>RS</given-names></name><name><surname>Green</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Mycobacterium tuberculosis cAMP receptor protein (Rv3676) differs from the <italic>Escherichia coli</italic> paradigm in its cAMP binding and DNA binding properties and transcription activation properties</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>7016</fpage><lpage>7027</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.047720</pub-id><pub-id pub-id-type="pmid">20028978</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tews</surname><given-names>I</given-names></name><name><surname>Findeisen</surname><given-names>F</given-names></name><name><surname>Sinning</surname><given-names>I</given-names></name><name><surname>Schultz</surname><given-names>A</given-names></name><name><surname>Schultz</surname><given-names>JE</given-names></name><name><surname>Linder</surname><given-names>JU</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The structure of a pH-sensing mycobacterial adenylyl cyclase holoenzyme</article-title><source>Science</source><volume>308</volume><fpage>1020</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1126/science.1107642</pub-id><pub-id pub-id-type="pmid">15890882</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Nunta</surname><given-names>K</given-names></name><name><surname>Cheyne</surname><given-names>A</given-names></name><name><surname>Fernandes</surname><given-names>N</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name><name><surname>Garza-Garcia</surname><given-names>A</given-names></name><name><surname>Larrouy-Maumus</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Expression of a novel mycobacterial phosphodiesterase successfully lowers camp levels resulting in reduced tolerance to cell wall-targeting antimicrobials</article-title><source>The Journal of Biological Chemistry</source><volume>298</volume><elocation-id>102151</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2022.102151</pub-id><pub-id pub-id-type="pmid">35718063</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>VanderVen</surname><given-names>BC</given-names></name><name><surname>Fahey</surname><given-names>RJ</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Abramovitch</surname><given-names>RB</given-names></name><name><surname>Memmott</surname><given-names>C</given-names></name><name><surname>Crowe</surname><given-names>AM</given-names></name><name><surname>Eltis</surname><given-names>LD</given-names></name><name><surname>Perola</surname><given-names>E</given-names></name><name><surname>Deininger</surname><given-names>DD</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Locher</surname><given-names>CP</given-names></name><name><surname>Russell</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Novel inhibitors of cholesterol degradation in mycobacterium tuberculosis reveal how the bacterium’s metabolism is constrained by the intracellular environment</article-title><source>PLOS Pathogens</source><volume>11</volume><elocation-id>e1004679</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004679</pub-id><pub-id pub-id-type="pmid">25675247</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Zimmermann</surname><given-names>M</given-names></name><name><surname>Goodwin</surname><given-names>MB</given-names></name><name><surname>Sauer</surname><given-names>U</given-names></name><name><surname>Barry</surname><given-names>CE</given-names></name><name><surname>Boshoff</surname><given-names>HI</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Fumarate reductase activity maintains an energized membrane in anaerobic mycobacterium tuberculosis</article-title><source>PLOS Pathogens</source><volume>7</volume><elocation-id>e1002287</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1002287</pub-id><pub-id pub-id-type="pmid">21998585</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilburn</surname><given-names>KM</given-names></name><name><surname>Montague</surname><given-names>CR</given-names></name><name><surname>Qin</surname><given-names>B</given-names></name><name><surname>Woods</surname><given-names>AK</given-names></name><name><surname>Love</surname><given-names>MS</given-names></name><name><surname>McNamara</surname><given-names>CW</given-names></name><name><surname>Schultz</surname><given-names>PG</given-names></name><name><surname>Southard</surname><given-names>TL</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Petrassi</surname><given-names>HM</given-names></name><name><surname>VanderVen</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Pharmacological and genetic activation of camp synthesis disrupts cholesterol utilization in mycobacterium tuberculosis</article-title><source>PLOS Pathogens</source><volume>18</volume><elocation-id>e1009862</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009862</pub-id><pub-id pub-id-type="pmid">35134095</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>AI</given-names></name><name><surname>Rock</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CRISPR interference (crispri) for targeted gene silencing in mycobacteria</article-title><source>Methods in Molecular Biology</source><volume>2314</volume><fpage>343</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-1460-0_16</pub-id><pub-id pub-id-type="pmid">34235662</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>DeJesus</surname><given-names>MA</given-names></name><name><surname>Rücker</surname><given-names>N</given-names></name><name><surname>Engelhart</surname><given-names>CA</given-names></name><name><surname>Wright</surname><given-names>MG</given-names></name><name><surname>Healy</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Ioerger</surname><given-names>TR</given-names></name><name><surname>Schnappinger</surname><given-names>D</given-names></name><name><surname>Ehrt</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Chemical genetic interaction profiling reveals determinants of intrinsic antibiotic resistance in mycobacterium tuberculosis</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>61</volume><elocation-id>e01334-17</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.01334-17</pub-id><pub-id pub-id-type="pmid">28893793</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81177.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rp50x72</institution-id><institution>University of the Witwatersrand</institution></institution-wrap><country>South Africa</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.07.07.499113" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.07.07.499113"/></front-stub><body><p>Bacteria living in stressful and fluctuating environments need to respond to changing conditions, and many species, including <italic>Mycobacterium tuberculosis</italic>, the causative agent of tuberculosis, use cyclic AMP (cAMP) as a secondary messenger to sense and respond to specific stimuli. What distinguishes <italic>M. tuberculosis</italic>, is that its genome encodes at least 15 adenylate cyclases, enzymes that synthesize cAMP from ATP. Using state-of-the-art methods in this important study, the authors characterized one specific adenylate cyclase, Rv3645, and convincingly demonstrate that it is the most significant contributor to cAMP levels, in addition to mediating fatty acid metabolism and antibiotic resistance. This manuscript will be of broad interest to readers in the field of tuberculosis drug discovery and bacterial metabolism.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81177.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rp50x72</institution-id><institution>University of the Witwatersrand</institution></institution-wrap><country>South Africa</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Jacobs</surname><given-names>William</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05cf8a891</institution-id><institution>Albert Einstein College of Medicine</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.07.07.499113">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.07.07.499113v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Cyclic AMP is a critical mediator of intrinsic drug resistance and fatty acid metabolism in <italic>M. tuberculosis</italic>&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Bavesh Kana as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: William Jacobs (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. The major objective of this study is to investigate the role of cAMP levels in LCFA metabolism. Thus, experiments monitoring the cAMP levels of ΔRv3645, ΔRv3645-Rv1339 KD, and WT-Rv1339 OE in media with/without LCFA with/without antibiotics are necessary to support the conclusions. Also, as shown in Supplementary Figure 1, only Rv3645 showed functional essentiality in resisting antibiotics. Thus, the authors include at least one adenylate cyclase (eg., Rv2212 as this enzyme is known to sense unsaturated fatty acids) as a negative control.</p><p>2. The reduction of cAMP levels is proposed as the primary mechanistic basis underlying ΔRv3645 hypersensitivity to multiple antibiotics. cAMP is synthesized by hydrolyzing ATP and releasing PPi. Thus, reduced biosynthesis of cAMP in Δrv3645 may be associated with the accumulation of ATP and depletion of PPi. As these metabolites are usually tightly regulated, increased drug sensitivity may be directly or indirectly associated with a dysregulation in ATP and PPi abundance, in addition to cAMP depletion. The authors should report ATP and PPi concentrations of Δrv3645 and Δrv3645-rv1339 OE.</p><p>3. Lines 182 – 184, sensitivity was not observed towards the odd chain fatty acids propionic acid and valeric acid, nor to cholesterol, ruling out propionate-derived toxicity as the source of the fatty acid sensitive growth phenotype. LCFA metabolism also can be toxic to <italic>M. tuberculosis</italic> if ICL aldehyde end products and ketoacidosis metabolites are accumulated, as reported in PMID: 28265055. In this context, quantification of ICL aldehyde end products and acetyl-CoA-derived ketoacidosis metabolites in ΔRv3645 and Rv3645KD is important.</p><p>4. Figure 5C, D: cAMP quantification should include the condition using media without LCFA as a negative control. The cAMP quantification experiment should also be done after treatment with antibiotics using LCFA. Figure 5G: cAMP level restoration should be confirmed using rv3645KD-rv3645cs and rv3645KD-rv3645cs-V59.</p><p>5. Reviewers did express concern regards PDIM, which can be lost during in vitro passage. Have the authors assayed their strains for the presence of PDIM? Or assessed these phenotypes in strains known to have PDIM?</p><p>Other issues that must be addressed:</p><p>1. Figure 1B: Provide the concentrations of each antibiotic used.</p><p>2. Figure 2B: Antibiotic uptake values of rv3645 KD should be included.</p><p>3. Line 211: lipid metabolism, should read &quot;long chain fatty acid metabolism&quot;.</p><p>4. Figure 1 legend, Please describe FDR.</p><p>5. Figure 2. It is not clear from the Figure or methods, what the concentration of BODIPY-Vancomycin used (2 ug/ml) corresponds to in terms of MIC. If the rv3645 KD strain is hypersensitive to Vancomycin, there is a possibility that the drug uptake measurements are biased towards cells that are still intact and have not yet been lysed, which might be similar to wild-type MTB. Maybe the rv3645 KD cells that hyper-accumulate Vancomycin are all lysed rapidly. Have the authors measured the kill-kinetics of Vancomycin over time? Or make a comparative assessment of values reported in the literature?</p><p>6. Figure 4. Rv1339 was identified in the suppressor screen and validated in subsequent experiments. What about Rv0805, the other main PDE? Did this come up on the screen? Also looking at the data in supplementary Figure 1a, interestingly the phenotype of rv0805 is opposite to that of rv1339 and mirrors that of rv3645. How can these observations be reconciled? Perhaps the authors can discuss this.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The study by Wong et al. investigates the role of Rv3645, one among 15 <italic>M. tuberculosis</italic> adenylated cyclase enzymes, and cyclic AMP as mediators that enable <italic>M. tuberculosis</italic> to catalyze LCFA (long chain fatty acid) to mitigate LCFA-induced metabolic toxicity and gain accompanied intrinsic drug tolerance. To this end, this study used the genome-wide CRISPRi library screening data (a previously published work) to pinpoint the rv3645 gene as a key candidate for the <italic>M. tuberculosis</italic> intrinsic drug tolerance. Using CRISPRi KD and genetic KO techniques targeting rv3645 and a Δrv3645 suppressor screen technique, authors observed that Rv3645 is the main functional adenylate cyclase enzyme used to biosynthesize cAMP for an effective LCFA metabolism and antibiotic effect evasion. This study is well-designed and experimentally solid to prove a new function of Rv3645. However, there are a couple of ways to improve the mechanistic bases, as noted below.</p><p>1. The major objective of this study is to propose the role of cAMP level in LCFA metabolism in <italic>M. tuberculosis</italic> intrinsic drug tolerance. Thus, this reviewer recommends the experiments monitoring the cAMP levels of Δrv3645, Δrv3645-rv1339 KD, and WT-rv1339 OE in media with/without LCFA with/without antibiotics. Also, as shown in Supplementary Figure 1, only rv3645 showed functional essentiality in resisting antibiotics. Thus, the authors include at least one adenylate cyclase (eg., rv2212 as this enzyme is known to sense unsaturated fatty acids) as a negative control.</p><p>2. Authors propose that reduction of cAMP levels is a main mechanistic basis underlying Δrv3645 hypersensitivity to multiple antibiotics. As already known, cAMP is synthesized by hydrolyzing ATP and releasing PPi. Thus, reduced biosynthesis of cAMP in Δrv3645 may be associated with the accumulation of ATP and depletion of PPi. As ATP and PPi concentrations are tightly regulated in gaining drug tolerance of <italic>M. tuberculosis</italic>, Δrv3645 drug sensitivity may be directly or indirectly associated with a dysregulation in ATP and PPi abundance in addition to cAMP depletion. Thus, to prove that Δrv3645 hypersensitivity to antibiotic effects is mainly due to cAMP depletion, this reviewer recommends including ATP and PPi concentrations of Δrv3645 and Δrv3645-rv1339 OE.</p><p>3. Lines 182 – 184 sensitivity was not observed towards the odd chain fatty acids propionic acid and valeric acid nor to cholesterol, ruling out propionate-derived toxicity as the source of the fatty acid sensitive growth phenotype: Even LCFA metabolism also can be toxic to <italic>M. tuberculosis</italic> if its ICL aldehyde endproducts and ketoacidosis metabolites are highly accumulated as reported in PMID: 28265055. Thus, this reviewer recommends the quantification of ICL aldehyde endproducts and acetyl-CoA-derived ketoacidosis metabolites in Δrv3645 and rv3645KD.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>One possible weakness in this work is that the phenotypes observed are strain specific. Did the authors perform similar experiments on other strains of TB?</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>– Figure 1 legend, Please describe FDR.</p><p>– Figure 2. It is not clear from the Figure or methods, what the concentration of BODIPY-Vancomycin used (2 ug/ml) corresponds to in terms of MIC. If the rv3645 KD strain is hypersensitive to Vancomycin, there is a possibility that the drug uptake measurements are biased towards cells that are still intact and have not yet been lysed, which might be similar to wild-type MTB. Maybe the rv3645 KD cells that hyper-accumulate Vancomycin are all lysed rapidly. Have the authors measured the kill-kinetics of Vancomycin over time?</p><p>– Figure 4. Rv1339 was identified in the suppressor screen and validated in subsequent experiments. What about Rv0805, the other main PDE? Did this come up in the screen? Also looking at the data in supplementary Figure 1a, interestingly the phenotype of rv0805 is opposite to that of rv1339 and mirrors that of rv3645. How can these observations be reconciled? Maybe the authors can discuss this.</p><p>– Figure 5H. The authors have speculated on the likely link between fatty acid metabolism and antibiotic sensitivity through activation of Mt-Pat and redox imbalance. These are easily testable hypotheses through expression analysis or metabolite analysis. This would greatly strengthen and fully validate their hypothesis.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81177.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. The major objective of this study is to investigate the role of cAMP levels in LCFA metabolism. Thus, experiments monitoring the cAMP levels of ΔRv3645, ΔRv3645-Rv1339 KD, and WT-Rv1339 OE in media with/without LCFA with/without antibiotics are necessary to support the conclusions. Also, as shown in Supplementary Figure 1, only Rv3645 showed functional essentiality in resisting antibiotics. Thus, the authors include at least one adenylate cyclase (eg., Rv2212 as this enzyme is known to sense unsaturated fatty acids) as a negative control.</p></disp-quote><p>To address the reviewers’ comment, we quantified cAMP levels in the following Mtb strains: WT, ∆<italic>rv3645</italic>+EV, ∆<italic>rv3645+rv3645,</italic> ∆<italic>rv3645</italic>+<italic>rv1339</italic> KD, and WT+<italic>rv1339</italic> OE. Strains were grown for 24 hours with/without oleic acid and with/without antibiotics. As can be seen in Figure 5 —figure supplement 5A, <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref> and <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref> the presence of oleic acid in the growth medium does not dramatically alter cAMP levels. Similar results were obtained when quantifying cAMP by ELISA or by mass spectrometry. We note that the magnitude of cAMP detected by ELISA is lower than quantified by mass spectrometry, likely reflecting differences in culture conditions and lysate preparation, but the relative changes in cAMP levels measured between strains remains similar across experiments.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-sa2-fig1-v2.tif"/></fig><fig id="sa2fig2" position="float"><label>Author response image 2.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-sa2-fig2-v2.tif"/></fig><p>The complemented strain ∆<italic>rv3645+rv3645</italic> produces higher cAMP levels under most conditions tested, consistent with the complementation construct modestly overexpressing <italic>rv3645</italic> from the <italic>hsp60</italic> promoter, as determined by RT-qPCR. To further address how cAMP may regulate LCFA catabolism in Mtb, we collaborated with the VanderVen lab to quantify [1-<sup>14</sup>C]-oleic acid uptake and metabolism in the following Mtb strains: WT, ∆<italic>rv3645</italic>+EV, ∆<italic>rv3645+rv3645,</italic> WT+<italic>rv1339</italic> OE and WT+<italic>rv1339</italic>(<italic>D180A</italic>) OE<italic>.</italic> As can be seen in <xref ref-type="fig" rid="sa2fig3">Author response image 3</xref> and Figure 5—figure supplement 3, reduced cAMP levels correlate with elevated oleic acid uptake and metabolism. Alterations in oleic acid uptake and metabolism were not mediated by altered levels of Mce1A, Mce1D, Mce1E, nor MceG levels. Our observation of elevated oleic acid uptake at low cAMP levels is consistent with prior results from the VanderVen lab that observed reduced oleic acid uptake in <italic>rv1339::Tn</italic> Mtb mutants in infected macrophages (PMID: 30735132). These results suggest that loss of <italic>rv1339</italic> suppresses the LCFA toxicity in ∆<italic>rv3645</italic> by reducing LCFA catabolism.</p><fig id="sa2fig3" position="float"><label>Author response image 3.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-sa2-fig3-v2.tif"/></fig><p>To test the effect of antibiotic treatment on cAMP levels, we exposed the same set of strains to 10 μM vancomycin (VAN), rifampicin (RIF), or linezolid (LZD) for 24 hours. All drugs were tested above their MIC90. cAMP was measured by ELISA. Whereas vancomycin did not alter cAMP levels, both rifampicin and linezolid led to large increases in cAMP in a manner partially dependent on <italic>rv3645</italic>. As shown in Figure 1D-G of the manuscript, <italic>rv3645</italic> KD are more sensitive to vancomycin and rifampicin but not linezolid. Thus, there is no correlation between the drugs that induce cAMP levels and those drugs that <italic>rv3645</italic> KD is sensitized to. We note that the ∆<italic>rv3645</italic>+<italic>rv1339</italic> KD strain shows only a modest increase in cAMP following LZD treatment in this particular experiment, but replicate experiments showed stronger cAMP induction in this strain, comparable to that observed in the WT strain. Taken together, these results suggest that cAMP produced by Rv3645 is necessary for H37Rv Mtb to maintain homeostasis, both with respect to LCFA uptake and catabolism and intrinsic drug resistance. While H37Rv Mtb can respond to alterations in cellular physiology, e.g. inhibition of transcription and/or translation, by altering cAMP levels in a manner largely dependent on Rv3645, it does not appear that an inducible cAMP stress response is critical to modulate LCFA uptake and catabolism nor intrinsic drug resistance.</p><p>To address the reviewers’ comment regarding the functional essentiality of Rv3645 in resisting antibiotics, we further validated the screen results by showing that knockdown of the alternative adenylate cyclases <italic>rv2212</italic>, <italic>rv1264</italic>, or <italic>rv1625c</italic> does not alter sensitivity to vancomycin.</p><p>These data are now included as Figure 3E-F, Figure 5F-G, and Figure 5 – figure supplements 3 and 5 in the revised manuscript and <xref ref-type="fig" rid="sa2fig4">Author response image 4</xref>.</p><fig id="sa2fig4" position="float"><label>Author response image 4.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-sa2-fig4-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>2. The reduction of cAMP levels is proposed as the primary mechanistic basis underlying ΔRv3645 hypersensitivity to multiple antibiotics. cAMP is synthesized by hydrolyzing ATP and releasing PPi. Thus, reduced biosynthesis of cAMP in Δrv3645 may be associated with the accumulation of ATP and depletion of PPi. As these metabolites are usually tightly regulated, increased drug sensitivity may be directly or indirectly associated with a dysregulation in ATP and PPi abundance, in addition to cAMP depletion. The authors should report ATP and PPi concentrations of Δrv3645 and Δrv3645-rv1339 OE.</p></disp-quote><p>We thank the reviewers for this suggestion. To address the reviewers’ comment, we quantified ATP and PPi levels by mass spectrometry in the following Mtb strains: WT, ∆<italic>rv3645</italic>+EV, ∆<italic>rv3645+rv3645,</italic> ∆<italic>rv3645</italic>+<italic>rv1339</italic> KD, and WT+<italic>rv1339</italic> OE. Strains were grown for 24 hours with a growth-inhibitory concentration of oleic acid. As can be seen in Figure 5 —figure supplement 2, ~10-30-fold reductions in cAMP levels (Figure 5C-E) do not dramatically alter ATP nor PPi levels in these strains.</p><disp-quote content-type="editor-comment"><p>3. Lines 182 – 184, sensitivity was not observed towards the odd chain fatty acids propionic acid and valeric acid, nor to cholesterol, ruling out propionate-derived toxicity as the source of the fatty acid sensitive growth phenotype. LCFA metabolism also can be toxic to M. tuberculosis if ICL aldehyde end products and ketoacidosis metabolites are accumulated, as reported in PMID: 28265055. In this context, quantification of ICL aldehyde end products and acetyl-CoA-derived ketoacidosis metabolites in ΔRv3645 and Rv3645KD is important.</p></disp-quote><p>This is a great suggestion and a hypothesis that we entertained early in this project. As the reviewer points out, LCFA can be toxic if isocitrate lyase (ICL) aldehyde end products accumulate. As reported in PMID: 28265055, ICL aldehyde end products accumulate when Mtb is deficient in malate synthase, encoded by the <italic>glcB</italic> gene. We reasoned that if ICL aldehyde end product accumulation was a source of LCFA toxicity and drug sensitivity in ∆<italic>rv3645</italic>, then ∆<italic>glcB</italic> and ∆<italic>rv3645</italic> Mtb strains should share similar phenotypes. This was generally not the case , and thus we concluded that the phenotypes observed in ∆<italic>rv3645</italic> Mtb strains occur by a mechanism distinct from ICL aldehyde end product accumulation.</p><p>Fatty acid toxicity: similar to ∆<italic>rv3645</italic>, ∆<italic>glcB</italic> mutants can be recovered in media lacking fatty acids, and fatty acids are toxic even in the presence of the alternative carbon sources glycerol and glucose (PMID: 28265055). However, the fatty acid susceptibility profiles of ∆<italic>rv3645</italic> and ∆<italic>glcB</italic> are distinct. Whereas ∆<italic>rv3645</italic> is only susceptible to LCFA including palmitic acid, oleic acid, and arachidonic acid (Figure 3B-D, Figure 3 – figure supplement 1B-G), ∆<italic>glcB</italic> is sensitive to short, medium, and long-chain fatty acids including acetate, propionate, butyrate, valerate, palmitic acid, oleic acid, and cholesterol (PMID: 28265055). Moreover, whereas chemical inactivation of Icl1 rescued growth of ∆<italic>glcB</italic> in the presence of LCFA (PMID: 28265055), we did not observe that knockdown of <italic>icl1</italic> rescued the palmitic acid toxicity in ∆<italic>rv3645</italic> in the suppressor screen (Figure 4A-B).</p><p>Intrinsic drug resistance: the chemical-genetic interactions observed for <italic>rv3645</italic> KD and <italic>glcB</italic> KD in our published CRISPRi screens are distinct (see <xref ref-type="fig" rid="sa2fig5">Author response image 5</xref>, PMID: 35637331).</p><fig id="sa2fig5" position="float"><label>Author response image 5.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-sa2-fig5-v2.tif"/></fig><p>Finally, to directly test if ICL aldehyde end product accumulation was a source of toxicity in ∆<italic>rv3645</italic> strains, we quantified the abundance of glyoxylate, butyryl-coenzyme A (butyryl-CoA), acetoacetate, and β-hydroxybutyrate by mass spectrometry in the following Mtb strains grown in 7H9-OADC: WT, <italic>rv3645</italic> KD + <italic>rv3645</italic><sup>CS</sup>, <italic>rv3645</italic> KD + <italic>rv3645</italic><sup>CR</sup>, and ∆<italic>rv3645</italic>. Consistent with our hypothesis that ICL aldehyde end product accumulation is not the source of fatty acid toxicity in ∆<italic>rv3645</italic>, the levels of these metabolites were unchanged across the tested Mtb strains. See <xref ref-type="fig" rid="sa2fig6">Author response image 6</xref>.</p><fig id="sa2fig6" position="float"><label>Author response image 6.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81177-sa2-fig6-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>4. Figure 5C, D: cAMP quantification should include the condition using media without LCFA as a negative control. The cAMP quantification experiment should also be done after treatment with antibiotics using LCFA. Figure 5G: cAMP level restoration should be confirmed using rv3645KD-rv3645cs and rv3645KD-rv3645cs-V59.</p></disp-quote><p>Please see our response to Essential Revision 1 to address the comments concerning Figure 5C-D.</p><p>Regarding the reviewer’s comment about Figure 5G, we first confirmed that 10 µM V-59 rescues the vancomycin sensitivity of ∆<italic>rv3645</italic> (the figure in the original manuscript submission utilized CRISPRi knockdown strains).</p><p>Next, we quantified cAMP by ELISA in the following Mtb strains: WT, ∆<italic>rv3645,</italic> and ∆<italic>rv3645 + rv3645</italic> in the presence or absence of 10 µM V-59. We observe higher levels of cAMP in all V-59 treated cultures, presumably explaining the rescue of ∆<italic>rv3645</italic> vancomycin sensitivity in the presence of V-59.</p><p>We replace Figure 5G with dose response curves of the ∆<italic>rv3645</italic> strains and include the cAMP measurements as Figure 5 – supplement 4.</p><disp-quote content-type="editor-comment"><p>5. Reviewers did express concern regards PDIM, which can be lost during in vitro passage. Have the authors assayed their strains for the presence of PDIM? Or assessed these phenotypes in strains known to have PDIM?</p></disp-quote><p>As the reviewers note, PDIM is easily lost during in vitro passaging of Mtb. The Mtb strains used in this manuscript have undergone several passages to sequentially clone CRISPRi and complementation/expression plasmids, or to engineer gene deletions, and thus we would not be surprised if our strains are PDIM–. On-going efforts in the lab to engineer uniformly PDIM+ genetic mutants in Mtb H37Rv have been unsuccessful. Thus, until such time a method exists to reliably maintain PDIM production in in vitro passaged Mtb, there is unfortunately not much that can be done to reliably assess the role of PDIM in these phenotypes.</p><disp-quote content-type="editor-comment"><p>Other issues that must be addressed:</p><p>1. Figure 1B: Provide the concentrations of each antibiotic used.</p></disp-quote><p>Corrected. These data are now included as Figure 1 —figure supplement 2 in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>2. Figure 2B: Antibiotic uptake values of rv3645 KD should be included.</p></disp-quote><p>Corrected. These data are now included as Figure 2 —figure supplement 2 in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>3. Line 211: lipid metabolism, should read &quot;long chain fatty acid metabolism&quot;.</p></disp-quote><p>Corrected.</p><disp-quote content-type="editor-comment"><p>4. Figure 1 legend, Please describe FDR.</p></disp-quote><p>Corrected.</p><disp-quote content-type="editor-comment"><p>5. Figure 2. It is not clear from the Figure or methods, what the concentration of BODIPY-Vancomycin used (2 ug/ml) corresponds to in terms of MIC. If the rv3645 KD strain is hypersensitive to Vancomycin, there is a possibility that the drug uptake measurements are biased towards cells that are still intact and have not yet been lysed, which might be similar to wild-type MTB. Maybe the rv3645 KD cells that hyper-accumulate Vancomycin are all lysed rapidly. Have the authors measured the kill-kinetics of Vancomycin over time? Or make a comparative assessment of values reported in the literature?</p></disp-quote><p>The concentration of BODIPY-vancomycin used (2 µg/mL or 1.16 µM) is above the MIC90 of the <italic>rv3645</italic> KD strain but below the MIC90 of the NT sgRNA and complemented control strains. We do not believe this should produce artifactual results because the BODIPY-vancomycin binding assays were performed over a short time period: 30 minutes or ~2% of the total time of a single Mtb cell cycle. We first confirmed that BODIPY-vancomycin showed similar potency to vancomycin. Because BODIPY-vancomycin is much more expensive than vancomycin, we next performed time-kill experiments using 1.16 µM vancomycin with the following Mtb strains: NT sgRNA, <italic>rv3645</italic> KD + <italic>rv3645<sup>CS</sup></italic>, and <italic>rv3645</italic> KD + <italic>rv3645<sup>CR</sup></italic>. 30 minutes of vancomycin exposure did not cause a drop in viable CFU for any of the strains. Thus, we do not think that the results of the BODIPY-vancomycin uptake experiment are influenced by the presence of dead or dying Mtb.</p><p>These data have been included as Figure 2 —figure supplement 1.</p><disp-quote content-type="editor-comment"><p>6. Figure 4. Rv1339 was identified in the suppressor screen and validated in subsequent experiments. What about Rv0805, the other main PDE? Did this come up on the screen? Also looking at the data in supplementary Figure 1a, interestingly the phenotype of rv0805 is opposite to that of rv1339 and mirrors that of rv3645. How can these observations be reconciled? Perhaps the authors can discuss this.</p></disp-quote><p>Existing evidence suggests that Rv1339 is the primary 3’,5’-cAMP PDE in Mtb, as detailed below.</p><p>We did not identify <italic>rv0805</italic> as a suppressor of palmitic acid toxicity in the ∆<italic>rv3645</italic> suppressor screen. Although Rv0805 is a cAMP phosphodiesterase, it is 150 times more active against 2’,3’-cAMP (a cAMP species associated with RNA degradation) than 3’,5’-cAMP (the product of adenylate cyclase) (PMID: 18757371). Consistent with this poor activity towards 3’,5’-cAMP, overexpression of Rv0805 resulted in only modest (~40%) reduction in 3’,5’-cAMP in Mtb (PMID: 19516256). Lastly, <italic>rv0805</italic> has a restricted phylogenetic distribution, being found in Mtb and closely related bacterial species, but not in other mycobacteria like <italic>M. smegmatis</italic> that also encode numerous adenylate cyclases (PMID: 35718063). Indeed, it is this restricted phylogenetic distribution of <italic>rv0805</italic> and the fact that <italic>M. smegmatis</italic> protein lysate was known to harbor 3’,5’-cAMP phosphodiesterase activity that was the rationale that ultimately led to the discovery of Rv1339 as an atypical 3’,5’-cAMP phosphodiesterase (PMID: 35718063). Thus, it appears the major role of Rv0805 in mycobacterial physiology is independent of 3’,5’-cAMP. We have included this section in a revised Discussion section of the manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>One possible weakness in this work is that the phenotypes observed are strain specific. Did the authors perform similar experiments on other strains of TB?</p></disp-quote><p>We thank Bill for this astute observation. In this work we focused solely on the reference Mtb strain H37Rv. Prior CRISPRi screening results suggest that <italic>rv3645</italic> may be a differentially essential gene between different Mtb strains (PMID: 34297925). To test the importance of cAMP in other strains of Mtb, we cloned the <italic>rv3645</italic> KD and <italic>rv1339</italic> OE plasmids into the lineage 2 strain HN878, in which <italic>rv3645</italic> appears non-essential (PMID: 34297925), and tested the resulting strains in dose-response MIC assays and agar plate-based fatty acid sensitivity spotting assays. We find that knockdown of <italic>rv3645</italic> or overexpression of <italic>rv1339</italic> in HN878 results in an intermediate sensitization to vancomycin compared to H37Rv. Moreover, overexpression of <italic>rv1339</italic> sensitized HN878 to palmitic acid. These results suggest a role for cAMP in mediating intrinsic drug resistance and fatty acid metabolism in Mtb beyond the reference strain H37Rv.</p><p>These data have been included as Figure 5 —figure supplement 6.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Specific comments:</p><p>– Figure 1 legend, Please describe FDR.</p><p>– Figure 2. It is not clear from the Figure or methods, what the concentration of BODIPY-Vancomycin used (2 ug/ml) corresponds to in terms of MIC. If the rv3645 KD strain is hypersensitive to Vancomycin, there is a possibility that the drug uptake measurements are biased towards cells that are still intact and have not yet been lysed, which might be similar to wild-type MTB. Maybe the rv3645 KD cells that hyper-accumulate Vancomycin are all lysed rapidly. Have the authors measured the kill-kinetics of Vancomycin over time?</p><p>– Figure 4. Rv1339 was identified in the suppressor screen and validated in subsequent experiments. What about Rv0805, the other main PDE? Did this come up in the screen? Also looking at the data in supplementary Figure 1a, interestingly the phenotype of rv0805 is opposite to that of rv1339 and mirrors that of rv3645. How can these observations be reconciled? Maybe the authors can discuss this.</p><p>– Figure 5H. The authors have speculated on the likely link between fatty acid metabolism and antibiotic sensitivity through activation of Mt-Pat and redox imbalance. These are easily testable hypotheses through expression analysis or metabolite analysis. This would greatly strengthen and fully validate their hypothesis.</p></disp-quote><p>We thank the reviewer for this comment. We agree that further analysis of phenotypes regulated by cAMP would strengthen our hypotheses. To this end, we have begun to interrogate the connection of cAMP with fatty acid metabolism. Please see our response to Essential Revision 1, demonstrating strains with <italic>rv3645</italic> deleted or overexpressing <italic>rv1339</italic> show increased uptake and catabolism of <sup>14</sup>C-oleic acid.</p></body></sub-article></article>